| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Muscle Spasticity | 28 | 2021 | 55 | 8.200 |
Why?
|
| Peripheral Nervous System Diseases | 45 | 2021 | 126 | 7.470 |
Why?
|
| Botulinum Toxins, Type A | 18 | 2021 | 41 | 6.780 |
Why?
|
| Neuralgia | 33 | 2023 | 128 | 6.750 |
Why?
|
| HIV Infections | 125 | 2019 | 2730 | 6.240 |
Why?
|
| Cerebrovascular Circulation | 29 | 2022 | 228 | 5.510 |
Why?
|
| Neuromuscular Agents | 12 | 2021 | 31 | 5.170 |
Why?
|
| Botulinum Toxins | 16 | 2021 | 39 | 5.020 |
Why?
|
| Polyneuropathies | 22 | 2021 | 51 | 4.050 |
Why?
|
| Diabetic Neuropathies | 7 | 2022 | 96 | 3.560 |
Why?
|
| Electroencephalography | 17 | 2023 | 409 | 3.550 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 7 | 2024 | 52 | 3.420 |
Why?
|
| Homeostasis | 24 | 2022 | 605 | 3.250 |
Why?
|
| Acquired Immunodeficiency Syndrome | 32 | 2012 | 228 | 2.840 |
Why?
|
| Stroke | 15 | 2023 | 1072 | 2.620 |
Why?
|
| AIDS Dementia Complex | 28 | 2018 | 51 | 2.580 |
Why?
|
| Neuromuscular Diseases | 13 | 2018 | 105 | 2.450 |
Why?
|
| Analgesics | 11 | 2021 | 194 | 2.430 |
Why?
|
| Capsaicin | 9 | 2022 | 25 | 2.410 |
Why?
|
| Speech Perception | 5 | 2023 | 83 | 2.310 |
Why?
|
| Blood Flow Velocity | 22 | 2022 | 406 | 2.290 |
Why?
|
| Blood Pressure | 27 | 2022 | 1736 | 2.240 |
Why?
|
| Humans | 416 | 2024 | 129847 | 2.120 |
Why?
|
| Evoked Potentials, Auditory | 7 | 2023 | 179 | 2.080 |
Why?
|
| Adult | 228 | 2024 | 35634 | 2.020 |
Why?
|
| Anti-HIV Agents | 33 | 2018 | 757 | 2.000 |
Why?
|
| Antiretroviral Therapy, Highly Active | 28 | 2019 | 267 | 2.000 |
Why?
|
| Anti-Retroviral Agents | 18 | 2019 | 231 | 1.970 |
Why?
|
| Heart Rate | 10 | 2019 | 804 | 1.750 |
Why?
|
| Middle Aged | 193 | 2021 | 31177 | 1.690 |
Why?
|
| HIV-1 | 24 | 2019 | 839 | 1.640 |
Why?
|
| Hearing Tests | 3 | 2022 | 47 | 1.580 |
Why?
|
| Male | 247 | 2021 | 63759 | 1.550 |
Why?
|
| Hearing Loss | 4 | 2024 | 209 | 1.520 |
Why?
|
| Signal Processing, Computer-Assisted | 14 | 2020 | 144 | 1.510 |
Why?
|
| Female | 249 | 2021 | 68829 | 1.510 |
Why?
|
| Pain Measurement | 18 | 2016 | 510 | 1.490 |
Why?
|
| Pain | 16 | 2018 | 791 | 1.480 |
Why?
|
| Cognition Disorders | 20 | 2015 | 505 | 1.450 |
Why?
|
| Double-Blind Method | 41 | 2020 | 1877 | 1.360 |
Why?
|
| Speech | 4 | 2023 | 73 | 1.290 |
Why?
|
| Brain | 22 | 2022 | 2677 | 1.260 |
Why?
|
| Diabetes Mellitus | 4 | 2022 | 1003 | 1.230 |
Why?
|
| Chronic Pain | 7 | 2019 | 253 | 1.220 |
Why?
|
| Reaction Time | 5 | 2018 | 411 | 1.200 |
Why?
|
| Carbon Dioxide | 7 | 2022 | 260 | 1.200 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 11 | 2011 | 37 | 1.160 |
Why?
|
| Treatment Outcome | 54 | 2023 | 10241 | 1.160 |
Why?
|
| Sleep, REM | 2 | 2018 | 34 | 1.160 |
Why?
|
| Signal-To-Noise Ratio | 5 | 2021 | 68 | 1.100 |
Why?
|
| Dystonic Disorders | 3 | 2021 | 24 | 1.060 |
Why?
|
| Acoustic Stimulation | 7 | 2024 | 327 | 1.050 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 6 | 2022 | 38 | 1.050 |
Why?
|
| Spinal Cord Diseases | 10 | 2009 | 41 | 1.030 |
Why?
|
| Neurotoxins | 4 | 2016 | 28 | 1.020 |
Why?
|
| Anti-Dyskinesia Agents | 5 | 2014 | 6 | 1.020 |
Why?
|
| Aged | 77 | 2021 | 22107 | 1.000 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 7 | 2022 | 66 | 0.970 |
Why?
|
| Muscular Diseases | 10 | 2004 | 109 | 0.920 |
Why?
|
| Extremities | 4 | 2020 | 127 | 0.890 |
Why?
|
| DNA, Mitochondrial | 4 | 2018 | 190 | 0.860 |
Why?
|
| Nervous System Diseases | 13 | 2017 | 252 | 0.830 |
Why?
|
| Sensory System Agents | 2 | 2016 | 3 | 0.820 |
Why?
|
| Multiple Myeloma | 2 | 2022 | 125 | 0.820 |
Why?
|
| Autonomic Nervous System Diseases | 5 | 2016 | 35 | 0.810 |
Why?
|
| RNA, Viral | 17 | 2019 | 620 | 0.790 |
Why?
|
| Algorithms | 17 | 2022 | 1617 | 0.780 |
Why?
|
| Essential Tremor | 2 | 2020 | 14 | 0.770 |
Why?
|
| Sensation Disorders | 4 | 2017 | 32 | 0.770 |
Why?
|
| Gene Editing | 1 | 2023 | 68 | 0.770 |
Why?
|
| Myalgia | 1 | 2021 | 13 | 0.760 |
Why?
|
| CRISPR-Cas Systems | 1 | 2023 | 109 | 0.750 |
Why?
|
| Young Adult | 37 | 2021 | 12467 | 0.740 |
Why?
|
| Evoked Potentials | 3 | 2019 | 127 | 0.740 |
Why?
|
| Deafness | 1 | 2023 | 80 | 0.730 |
Why?
|
| Arterial Pressure | 4 | 2020 | 119 | 0.730 |
Why?
|
| Neuropsychological Tests | 27 | 2019 | 1016 | 0.720 |
Why?
|
| Aged, 80 and over | 28 | 2021 | 7066 | 0.720 |
Why?
|
| Central Nervous System Diseases | 3 | 2018 | 69 | 0.710 |
Why?
|
| Shoulder | 2 | 2020 | 86 | 0.710 |
Why?
|
| Divorce | 1 | 2021 | 10 | 0.700 |
Why?
|
| Movement | 10 | 2017 | 270 | 0.690 |
Why?
|
| Help-Seeking Behavior | 1 | 2021 | 19 | 0.690 |
Why?
|
| Models, Biological | 9 | 2014 | 1724 | 0.690 |
Why?
|
| Quality of Life | 13 | 2021 | 2695 | 0.680 |
Why?
|
| Clubfoot | 1 | 2020 | 6 | 0.680 |
Why?
|
| Upper Extremity | 3 | 2017 | 95 | 0.670 |
Why?
|
| Complementary Therapies | 1 | 2021 | 87 | 0.670 |
Why?
|
| JC Virus | 6 | 2011 | 23 | 0.660 |
Why?
|
| Wakefulness | 2 | 2018 | 120 | 0.660 |
Why?
|
| Models, Neurological | 9 | 2017 | 240 | 0.660 |
Why?
|
| Neuromuscular Blocking Agents | 3 | 2008 | 24 | 0.660 |
Why?
|
| Diagnostic Techniques, Neurological | 1 | 2019 | 9 | 0.640 |
Why?
|
| Monitoring, Physiologic | 2 | 2017 | 266 | 0.640 |
Why?
|
| Disability Evaluation | 4 | 2017 | 285 | 0.630 |
Why?
|
| Auditory Threshold | 2 | 2024 | 40 | 0.630 |
Why?
|
| Infant, Premature, Diseases | 1 | 2020 | 93 | 0.630 |
Why?
|
| Hemodynamics | 3 | 2021 | 1094 | 0.630 |
Why?
|
| Neurologic Examination | 9 | 2014 | 114 | 0.620 |
Why?
|
| Anesthesia, Intravenous | 1 | 2018 | 15 | 0.620 |
Why?
|
| Infant, Premature | 2 | 2020 | 541 | 0.620 |
Why?
|
| Cerebrospinal Fluid | 5 | 2019 | 92 | 0.620 |
Why?
|
| Muscle, Skeletal | 11 | 2017 | 1644 | 0.610 |
Why?
|
| Hepatitis C | 7 | 2015 | 244 | 0.610 |
Why?
|
| Phonetics | 1 | 2019 | 45 | 0.610 |
Why?
|
| Hemochromatosis Protein | 1 | 2018 | 3 | 0.610 |
Why?
|
| Pregabalin | 3 | 2014 | 8 | 0.610 |
Why?
|
| Reproducibility of Results | 21 | 2022 | 3089 | 0.600 |
Why?
|
| HIV | 12 | 2017 | 227 | 0.600 |
Why?
|
| Motor Endplate | 2 | 2009 | 15 | 0.600 |
Why?
|
| Anticonvulsants | 4 | 2012 | 209 | 0.600 |
Why?
|
| Dose-Response Relationship, Drug | 16 | 2020 | 2016 | 0.600 |
Why?
|
| Tympanic Membrane | 1 | 2018 | 23 | 0.590 |
Why?
|
| Propofol | 1 | 2018 | 63 | 0.590 |
Why?
|
| Intracranial Pressure | 1 | 2018 | 45 | 0.580 |
Why?
|
| Viral Load | 20 | 2019 | 449 | 0.580 |
Why?
|
| Paraparesis, Spastic | 1 | 2017 | 2 | 0.580 |
Why?
|
| Blepharospasm | 3 | 2016 | 7 | 0.570 |
Why?
|
| Exposure to Violence | 1 | 2018 | 16 | 0.570 |
Why?
|
| Zidovudine | 9 | 1999 | 78 | 0.570 |
Why?
|
| CD4 Lymphocyte Count | 20 | 2019 | 267 | 0.570 |
Why?
|
| Tremor | 2 | 2017 | 60 | 0.570 |
Why?
|
| Analgesics, Non-Narcotic | 4 | 2012 | 122 | 0.570 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2018 | 82 | 0.570 |
Why?
|
| Pyrimidines | 6 | 2022 | 458 | 0.570 |
Why?
|
| Muscle Weakness | 5 | 2012 | 85 | 0.570 |
Why?
|
| Peripheral Nerves | 10 | 2014 | 70 | 0.560 |
Why?
|
| Cell Hypoxia | 1 | 2018 | 234 | 0.560 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2010 | 168 | 0.560 |
Why?
|
| Love | 1 | 2017 | 10 | 0.560 |
Why?
|
| Acetylcholine Release Inhibitors | 2 | 2017 | 3 | 0.560 |
Why?
|
| Pyrazoles | 5 | 2022 | 403 | 0.560 |
Why?
|
| Anesthetics, Local | 5 | 2007 | 79 | 0.550 |
Why?
|
| Stroke Rehabilitation | 5 | 2018 | 40 | 0.550 |
Why?
|
| Urban Population | 3 | 2018 | 443 | 0.550 |
Why?
|
| Object Attachment | 1 | 2017 | 41 | 0.540 |
Why?
|
| Exercise Therapy | 2 | 2018 | 413 | 0.540 |
Why?
|
| Valsalva Maneuver | 1 | 2016 | 8 | 0.530 |
Why?
|
| Adolescent Development | 1 | 2017 | 84 | 0.530 |
Why?
|
| Adolescent | 38 | 2021 | 20451 | 0.520 |
Why?
|
| Patient-Centered Care | 2 | 2021 | 508 | 0.520 |
Why?
|
| Sensitivity and Specificity | 14 | 2019 | 1847 | 0.520 |
Why?
|
| Self Report | 3 | 2016 | 800 | 0.510 |
Why?
|
| Torticollis | 1 | 2016 | 12 | 0.510 |
Why?
|
| Practice Guidelines as Topic | 5 | 2017 | 1514 | 0.510 |
Why?
|
| Analgesics, Opioid | 5 | 2021 | 925 | 0.500 |
Why?
|
| Reverse Transcriptase Inhibitors | 5 | 2012 | 83 | 0.500 |
Why?
|
| Diagnosis, Computer-Assisted | 3 | 2006 | 86 | 0.500 |
Why?
|
| 4-Aminopyridine | 1 | 2015 | 24 | 0.490 |
Why?
|
| Potassium Channel Blockers | 1 | 2015 | 36 | 0.490 |
Why?
|
| Violence | 1 | 2018 | 244 | 0.480 |
Why?
|
| Electroretinography | 1 | 2015 | 45 | 0.470 |
Why?
|
| Research Design | 3 | 2019 | 1045 | 0.470 |
Why?
|
| Arteries | 2 | 2015 | 266 | 0.470 |
Why?
|
| Severity of Illness Index | 19 | 2018 | 2739 | 0.470 |
Why?
|
| Headache | 1 | 2016 | 151 | 0.470 |
Why?
|
| Vascular Diseases | 1 | 2017 | 240 | 0.470 |
Why?
|
| Outpatients | 2 | 2016 | 375 | 0.470 |
Why?
|
| Expert Testimony | 1 | 2015 | 36 | 0.460 |
Why?
|
| Clinical Trials as Topic | 10 | 2014 | 1005 | 0.460 |
Why?
|
| Aging | 5 | 2011 | 1774 | 0.460 |
Why?
|
| Neural Conduction | 14 | 2021 | 83 | 0.460 |
Why?
|
| Models, Cardiovascular | 3 | 2014 | 192 | 0.460 |
Why?
|
| Optic Nerve Diseases | 1 | 2015 | 34 | 0.460 |
Why?
|
| DNA Transposable Elements | 3 | 2024 | 119 | 0.450 |
Why?
|
| Skin | 5 | 2014 | 725 | 0.450 |
Why?
|
| Pain Perception | 1 | 2015 | 42 | 0.450 |
Why?
|
| AIDS-Related Opportunistic Infections | 4 | 2011 | 123 | 0.450 |
Why?
|
| Altitude | 1 | 2018 | 462 | 0.450 |
Why?
|
| Retinal Ganglion Cells | 1 | 2015 | 101 | 0.440 |
Why?
|
| Prospective Studies | 26 | 2020 | 7158 | 0.440 |
Why?
|
| Follow-Up Studies | 15 | 2022 | 4896 | 0.440 |
Why?
|
| Toes | 1 | 2013 | 15 | 0.440 |
Why?
|
| Injections, Intramuscular | 6 | 2020 | 115 | 0.430 |
Why?
|
| Particle Accelerators | 1 | 2013 | 10 | 0.430 |
Why?
|
| Evidence-Based Medicine | 9 | 2013 | 716 | 0.430 |
Why?
|
| Autonomic Nervous System | 3 | 2018 | 75 | 0.430 |
Why?
|
| Diabetic Foot | 1 | 2013 | 25 | 0.430 |
Why?
|
| Pruritus | 1 | 2013 | 58 | 0.430 |
Why?
|
| Multivariate Analysis | 12 | 2018 | 1501 | 0.420 |
Why?
|
| Arm | 3 | 2014 | 107 | 0.420 |
Why?
|
| Paralysis | 1 | 2014 | 69 | 0.420 |
Why?
|
| Piperidines | 5 | 2022 | 200 | 0.420 |
Why?
|
| Inhalation | 1 | 2013 | 28 | 0.410 |
Why?
|
| Exhalation | 1 | 2013 | 39 | 0.410 |
Why?
|
| Immunologic Factors | 3 | 2010 | 229 | 0.410 |
Why?
|
| Paresis | 2 | 2012 | 30 | 0.410 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2022 | 1560 | 0.400 |
Why?
|
| Radiotherapy | 1 | 2013 | 185 | 0.400 |
Why?
|
| Blood Pressure Determination | 6 | 2020 | 148 | 0.400 |
Why?
|
| Methionine | 4 | 2004 | 155 | 0.400 |
Why?
|
| Retina | 1 | 2015 | 283 | 0.400 |
Why?
|
| Herbicides | 3 | 2020 | 23 | 0.400 |
Why?
|
| Polyomavirus Infections | 2 | 2011 | 28 | 0.400 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2018 | 813 | 0.400 |
Why?
|
| Posture | 6 | 2017 | 175 | 0.390 |
Why?
|
| Adolescent Behavior | 1 | 2017 | 507 | 0.390 |
Why?
|
| Respiration | 1 | 2013 | 193 | 0.390 |
Why?
|
| Small Fiber Neuropathy | 2 | 2022 | 2 | 0.390 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2016 | 374 | 0.380 |
Why?
|
| Self-Injurious Behavior | 1 | 2013 | 124 | 0.380 |
Why?
|
| Hemiplegia | 2 | 2009 | 21 | 0.380 |
Why?
|
| Feedback, Sensory | 4 | 2018 | 23 | 0.380 |
Why?
|
| Cognitive Dysfunction | 4 | 2018 | 347 | 0.380 |
Why?
|
| Thalidomide | 4 | 2019 | 32 | 0.380 |
Why?
|
| Activities of Daily Living | 8 | 2018 | 384 | 0.380 |
Why?
|
| Movement Disorders | 2 | 2013 | 52 | 0.380 |
Why?
|
| Immunoglobulins, Intravenous | 3 | 2009 | 130 | 0.380 |
Why?
|
| Pain Management | 3 | 2022 | 334 | 0.380 |
Why?
|
| Electromyography | 10 | 2021 | 381 | 0.380 |
Why?
|
| Disease Management | 4 | 2021 | 592 | 0.370 |
Why?
|
| Respiratory Mechanics | 2 | 2013 | 65 | 0.370 |
Why?
|
| Triazines | 2 | 2003 | 38 | 0.370 |
Why?
|
| Cross-Sectional Studies | 20 | 2019 | 5085 | 0.370 |
Why?
|
| HIV Reverse Transcriptase | 3 | 2012 | 30 | 0.370 |
Why?
|
| Vocal Cord Paralysis | 3 | 2000 | 29 | 0.370 |
Why?
|
| Photic Stimulation | 4 | 2020 | 242 | 0.370 |
Why?
|
| Electromagnetic Fields | 1 | 2011 | 23 | 0.370 |
Why?
|
| Sensory Receptor Cells | 5 | 2015 | 103 | 0.360 |
Why?
|
| Thiophenes | 2 | 2013 | 117 | 0.360 |
Why?
|
| Drug Administration Schedule | 11 | 2019 | 766 | 0.360 |
Why?
|
| Hearing Loss, Sensorineural | 2 | 2023 | 56 | 0.360 |
Why?
|
| Rituximab | 6 | 2019 | 164 | 0.350 |
Why?
|
| Evoked Potentials, Somatosensory | 4 | 2000 | 33 | 0.350 |
Why?
|
| Psychometrics | 1 | 2015 | 701 | 0.350 |
Why?
|
| Biomarkers | 12 | 2023 | 3971 | 0.350 |
Why?
|
| Cell Phone | 1 | 2011 | 70 | 0.340 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2022 | 957 | 0.340 |
Why?
|
| Disaster Planning | 2 | 2002 | 83 | 0.330 |
Why?
|
| Community Participation | 2 | 2002 | 125 | 0.330 |
Why?
|
| Didanosine | 2 | 2008 | 13 | 0.330 |
Why?
|
| Hypercapnia | 6 | 2017 | 50 | 0.330 |
Why?
|
| Time Factors | 19 | 2019 | 6550 | 0.330 |
Why?
|
| Computer Simulation | 8 | 2014 | 941 | 0.320 |
Why?
|
| Genotype | 7 | 2018 | 1829 | 0.320 |
Why?
|
| Range of Motion, Articular | 6 | 2018 | 370 | 0.320 |
Why?
|
| Hyperemia | 1 | 2010 | 48 | 0.320 |
Why?
|
| Neurocognitive Disorders | 3 | 2018 | 26 | 0.320 |
Why?
|
| Regression Analysis | 10 | 2018 | 998 | 0.320 |
Why?
|
| Waldenstrom Macroglobulinemia | 2 | 2020 | 11 | 0.320 |
Why?
|
| Risk Assessment | 6 | 2017 | 3269 | 0.320 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2009 | 14 | 0.320 |
Why?
|
| Animals | 35 | 2024 | 35409 | 0.310 |
Why?
|
| Cohort Studies | 22 | 2021 | 5444 | 0.310 |
Why?
|
| Ritonavir | 4 | 2022 | 73 | 0.310 |
Why?
|
| Splenectomy | 1 | 2009 | 58 | 0.310 |
Why?
|
| Granuloma, Plasma Cell | 1 | 2009 | 13 | 0.310 |
Why?
|
| Linear Models | 6 | 2018 | 822 | 0.310 |
Why?
|
| Umbilical Cord | 2 | 2020 | 83 | 0.310 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2009 | 18 | 0.310 |
Why?
|
| Parasympatholytics | 3 | 1998 | 12 | 0.310 |
Why?
|
| Muscle Relaxants, Central | 1 | 2008 | 11 | 0.300 |
Why?
|
| Clonidine | 1 | 2008 | 27 | 0.300 |
Why?
|
| Hearing | 4 | 2024 | 135 | 0.300 |
Why?
|
| Herbicide Resistance | 3 | 2020 | 3 | 0.300 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2014 | 482 | 0.300 |
Why?
|
| Psychomotor Performance | 5 | 2020 | 312 | 0.300 |
Why?
|
| Antidepressive Agents, Tricyclic | 2 | 2007 | 30 | 0.300 |
Why?
|
| Dexamethasone | 2 | 2022 | 352 | 0.290 |
Why?
|
| Muscular Atrophy, Spinal | 2 | 1998 | 22 | 0.290 |
Why?
|
| Calcium Phosphates | 2 | 2004 | 25 | 0.290 |
Why?
|
| Mononeuropathies | 2 | 2005 | 3 | 0.280 |
Why?
|
| Antidepressive Agents | 2 | 2007 | 229 | 0.280 |
Why?
|
| Data Interpretation, Statistical | 7 | 2020 | 338 | 0.280 |
Why?
|
| Protease Inhibitors | 1 | 2008 | 107 | 0.280 |
Why?
|
| Injections | 2 | 2020 | 174 | 0.280 |
Why?
|
| Mianserin | 1 | 2007 | 5 | 0.280 |
Why?
|
| Polycythemia Vera | 1 | 2007 | 12 | 0.280 |
Why?
|
| Drug Tolerance | 2 | 2007 | 90 | 0.280 |
Why?
|
| Zinc | 2 | 2020 | 286 | 0.270 |
Why?
|
| Interneurons | 3 | 2015 | 120 | 0.270 |
Why?
|
| CD4-Positive T-Lymphocytes | 11 | 2018 | 1058 | 0.270 |
Why?
|
| Monte Carlo Method | 5 | 2020 | 143 | 0.270 |
Why?
|
| Anxiety Disorders | 3 | 2018 | 357 | 0.270 |
Why?
|
| Birth Weight | 2 | 2008 | 505 | 0.270 |
Why?
|
| Risk Factors | 18 | 2019 | 9801 | 0.270 |
Why?
|
| Confidence Intervals | 4 | 2021 | 318 | 0.260 |
Why?
|
| Fentanyl | 1 | 2007 | 81 | 0.260 |
Why?
|
| Motor Neurons | 3 | 2015 | 233 | 0.250 |
Why?
|
| Cell Line | 10 | 2023 | 2780 | 0.250 |
Why?
|
| Castleman Disease | 2 | 2017 | 13 | 0.250 |
Why?
|
| Biomedical Engineering | 1 | 2005 | 27 | 0.240 |
Why?
|
| Signal Transduction | 6 | 2024 | 4935 | 0.240 |
Why?
|
| Magnetic Resonance Imaging | 13 | 2018 | 3397 | 0.240 |
Why?
|
| Education, Professional | 1 | 2005 | 18 | 0.240 |
Why?
|
| Transdermal Patch | 2 | 2016 | 15 | 0.240 |
Why?
|
| Lower Extremity | 3 | 2018 | 407 | 0.240 |
Why?
|
| Physical Therapy Modalities | 3 | 2018 | 296 | 0.240 |
Why?
|
| Median Nerve | 4 | 2021 | 23 | 0.240 |
Why?
|
| Constriction | 3 | 2020 | 46 | 0.240 |
Why?
|
| Delphi Technique | 2 | 2017 | 227 | 0.240 |
Why?
|
| Infant | 9 | 2023 | 9018 | 0.240 |
Why?
|
| Computer-Assisted Instruction | 1 | 2005 | 61 | 0.230 |
Why?
|
| Lymphoma, Mantle-Cell | 2 | 2016 | 19 | 0.230 |
Why?
|
| Oligopeptides | 2 | 2022 | 260 | 0.230 |
Why?
|
| Cross-Over Studies | 5 | 2015 | 521 | 0.230 |
Why?
|
| Education, Distance | 1 | 2005 | 45 | 0.230 |
Why?
|
| Memantine | 4 | 2010 | 15 | 0.230 |
Why?
|
| Medical Audit | 2 | 2015 | 74 | 0.230 |
Why?
|
| Laparoscopy | 1 | 2009 | 447 | 0.230 |
Why?
|
| Dideoxynucleosides | 4 | 2003 | 20 | 0.230 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2024 | 33 | 0.230 |
Why?
|
| Surveys and Questionnaires | 7 | 2020 | 5437 | 0.230 |
Why?
|
| 2,4-Dichlorophenoxyacetic Acid | 2 | 2017 | 10 | 0.230 |
Why?
|
| Plasma | 4 | 2023 | 206 | 0.230 |
Why?
|
| Cognition | 2 | 2016 | 1125 | 0.230 |
Why?
|
| Therapies, Investigational | 2 | 2014 | 17 | 0.230 |
Why?
|
| Cerebral Cortex | 4 | 2016 | 439 | 0.230 |
Why?
|
| Gray Matter | 4 | 2018 | 81 | 0.230 |
Why?
|
| Apolipoprotein E4 | 2 | 2016 | 35 | 0.220 |
Why?
|
| Benzoxazines | 3 | 2015 | 30 | 0.220 |
Why?
|
| Comorbidity | 10 | 2018 | 1551 | 0.220 |
Why?
|
| Pyridazines | 2 | 2016 | 54 | 0.220 |
Why?
|
| Prognosis | 9 | 2019 | 3773 | 0.220 |
Why?
|
| Bone Cements | 1 | 2004 | 42 | 0.220 |
Why?
|
| Grasshoppers | 6 | 2017 | 6 | 0.220 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2016 | 79 | 0.220 |
Why?
|
| Respiratory Paralysis | 1 | 2004 | 3 | 0.220 |
Why?
|
| Phrenic Nerve | 1 | 2004 | 6 | 0.220 |
Why?
|
| Exons | 3 | 2024 | 341 | 0.220 |
Why?
|
| Lopinavir | 2 | 2022 | 30 | 0.220 |
Why?
|
| Lidocaine | 2 | 2004 | 41 | 0.220 |
Why?
|
| Statistics as Topic | 3 | 2019 | 306 | 0.220 |
Why?
|
| Endogenous Retroviruses | 1 | 2024 | 34 | 0.220 |
Why?
|
| Action Potentials | 5 | 2015 | 485 | 0.220 |
Why?
|
| Minority Groups | 3 | 2018 | 250 | 0.220 |
Why?
|
| Central Nervous System | 3 | 2014 | 256 | 0.210 |
Why?
|
| Wrist | 3 | 2008 | 54 | 0.210 |
Why?
|
| Tibial Fractures | 1 | 2004 | 72 | 0.210 |
Why?
|
| Syphilis | 2 | 2013 | 32 | 0.210 |
Why?
|
| Foramen Ovale, Patent | 1 | 2023 | 10 | 0.210 |
Why?
|
| Proteins | 5 | 2023 | 944 | 0.210 |
Why?
|
| Depression | 8 | 2016 | 1323 | 0.210 |
Why?
|
| Tibia | 1 | 2004 | 172 | 0.200 |
Why?
|
| Saccharomyces cerevisiae Proteins | 4 | 2011 | 383 | 0.200 |
Why?
|
| Drug Therapy, Combination | 12 | 2015 | 1042 | 0.200 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2023 | 88 | 0.200 |
Why?
|
| Audiometry | 1 | 2023 | 27 | 0.200 |
Why?
|
| Alternative Splicing | 1 | 2024 | 216 | 0.200 |
Why?
|
| Disasters | 2 | 2015 | 94 | 0.200 |
Why?
|
| Neurofeedback | 1 | 2022 | 4 | 0.200 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2016 | 253 | 0.200 |
Why?
|
| Diagnosis, Differential | 7 | 2017 | 1434 | 0.200 |
Why?
|
| Klebsiella pneumoniae | 1 | 2022 | 42 | 0.200 |
Why?
|
| Statistics, Nonparametric | 5 | 2016 | 422 | 0.200 |
Why?
|
| Nonlinear Dynamics | 2 | 2014 | 88 | 0.200 |
Why?
|
| Gene Knockout Techniques | 1 | 2023 | 109 | 0.200 |
Why?
|
| Administration, Cutaneous | 4 | 2012 | 124 | 0.200 |
Why?
|
| Venous Thromboembolism | 3 | 2015 | 287 | 0.200 |
Why?
|
| Social Support | 2 | 2018 | 587 | 0.200 |
Why?
|
| Mutation | 11 | 2022 | 3706 | 0.190 |
Why?
|
| Placebos | 7 | 2008 | 201 | 0.190 |
Why?
|
| Psychiatric Status Rating Scales | 9 | 2016 | 534 | 0.190 |
Why?
|
| Basal Ganglia | 3 | 2018 | 53 | 0.190 |
Why?
|
| Relief Work | 1 | 2002 | 19 | 0.190 |
Why?
|
| Adenine | 4 | 2022 | 257 | 0.190 |
Why?
|
| Substance-Related Disorders | 9 | 2016 | 1023 | 0.190 |
Why?
|
| Mitochondria | 3 | 2018 | 875 | 0.190 |
Why?
|
| Predictive Value of Tests | 10 | 2015 | 1951 | 0.190 |
Why?
|
| Bendamustine Hydrochloride | 3 | 2017 | 11 | 0.190 |
Why?
|
| Fracture Fixation, Internal | 1 | 2004 | 213 | 0.190 |
Why?
|
| Migraine Disorders | 1 | 2023 | 101 | 0.190 |
Why?
|
| Analysis of Variance | 8 | 2013 | 1291 | 0.180 |
Why?
|
| September 11 Terrorist Attacks | 1 | 2021 | 31 | 0.180 |
Why?
|
| Probability | 2 | 2020 | 304 | 0.180 |
Why?
|
| Evoked Potentials, Visual | 3 | 2015 | 35 | 0.180 |
Why?
|
| False Positive Reactions | 2 | 2020 | 114 | 0.180 |
Why?
|
| White Matter | 3 | 2018 | 135 | 0.180 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2004 | 340 | 0.180 |
Why?
|
| Emergency Responders | 1 | 2021 | 35 | 0.180 |
Why?
|
| Alleles | 3 | 2018 | 843 | 0.180 |
Why?
|
| Carpal Tunnel Syndrome | 1 | 2021 | 27 | 0.180 |
Why?
|
| Internet | 1 | 2005 | 620 | 0.180 |
Why?
|
| Lymphoma, Follicular | 2 | 2019 | 40 | 0.180 |
Why?
|
| New Zealand | 5 | 2015 | 45 | 0.180 |
Why?
|
| Anxiety | 4 | 2017 | 976 | 0.180 |
Why?
|
| Child | 17 | 2023 | 20962 | 0.180 |
Why?
|
| Mammals | 1 | 2023 | 274 | 0.180 |
Why?
|
| Pilot Projects | 6 | 2018 | 1597 | 0.180 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2000 | 14 | 0.180 |
Why?
|
| Aspartic Acid | 3 | 2018 | 80 | 0.170 |
Why?
|
| Noise | 1 | 2021 | 67 | 0.170 |
Why?
|
| Nerve Compression Syndromes | 1 | 2000 | 23 | 0.170 |
Why?
|
| Homovanillic Acid | 1 | 2000 | 10 | 0.170 |
Why?
|
| Electric Stimulation | 2 | 2017 | 269 | 0.170 |
Why?
|
| Volunteers | 1 | 2000 | 29 | 0.170 |
Why?
|
| Numerical Analysis, Computer-Assisted | 1 | 2000 | 19 | 0.170 |
Why?
|
| Carotid Artery, Internal | 1 | 2000 | 41 | 0.170 |
Why?
|
| Protective Factors | 2 | 2018 | 91 | 0.170 |
Why?
|
| Prednisone | 4 | 2016 | 234 | 0.170 |
Why?
|
| Spasm | 1 | 2000 | 20 | 0.170 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2015 | 397 | 0.170 |
Why?
|
| Burkitt Lymphoma | 1 | 2000 | 56 | 0.170 |
Why?
|
| Audiometry, Evoked Response | 1 | 2020 | 11 | 0.170 |
Why?
|
| Electrodiagnosis | 3 | 2010 | 15 | 0.170 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2012 | 94 | 0.170 |
Why?
|
| Geriatrics | 1 | 2021 | 81 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 5 | 2014 | 1368 | 0.170 |
Why?
|
| Diphtheria | 1 | 2000 | 20 | 0.170 |
Why?
|
| Disease Outbreaks | 3 | 1999 | 349 | 0.160 |
Why?
|
| Anticoagulants | 2 | 2015 | 637 | 0.160 |
Why?
|
| Bandages | 2 | 2010 | 32 | 0.160 |
Why?
|
| Spouses | 1 | 2021 | 103 | 0.160 |
Why?
|
| Vasomotor System | 2 | 2010 | 44 | 0.160 |
Why?
|
| Carotid Stenosis | 1 | 2000 | 84 | 0.160 |
Why?
|
| Interferon-gamma | 1 | 2023 | 773 | 0.160 |
Why?
|
| Ultrasonography | 4 | 2021 | 713 | 0.160 |
Why?
|
| Saccharomyces cerevisiae | 5 | 2018 | 530 | 0.160 |
Why?
|
| Fibrinogen | 3 | 2010 | 164 | 0.160 |
Why?
|
| Leukemia, B-Cell | 1 | 2019 | 14 | 0.160 |
Why?
|
| Radiography | 7 | 2009 | 800 | 0.160 |
Why?
|
| Electrophysiology | 4 | 2008 | 213 | 0.160 |
Why?
|
| Geriatric Assessment | 1 | 2021 | 205 | 0.160 |
Why?
|
| Macrophages, Alveolar | 1 | 2022 | 389 | 0.160 |
Why?
|
| Mexican Americans | 2 | 1998 | 113 | 0.160 |
Why?
|
| Reflex | 3 | 2017 | 65 | 0.160 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 5 | 1990 | 25 | 0.160 |
Why?
|
| Iron | 3 | 2018 | 285 | 0.160 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2020 | 175 | 0.160 |
Why?
|
| Mammary Glands, Animal | 1 | 2020 | 128 | 0.160 |
Why?
|
| Watchful Waiting | 1 | 2019 | 67 | 0.160 |
Why?
|
| Consciousness Monitors | 1 | 2018 | 2 | 0.160 |
Why?
|
| Speech Acoustics | 1 | 2019 | 12 | 0.160 |
Why?
|
| HIV Seropositivity | 5 | 2011 | 120 | 0.150 |
Why?
|
| Spinal Cord Injuries | 1 | 2022 | 194 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 4 | 2016 | 86 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2015 | 1368 | 0.150 |
Why?
|
| Sustained Virologic Response | 1 | 2019 | 37 | 0.150 |
Why?
|
| Biomedical Research | 3 | 2014 | 640 | 0.150 |
Why?
|
| Sample Size | 1 | 2019 | 116 | 0.150 |
Why?
|
| Oxyhemoglobins | 1 | 2018 | 21 | 0.150 |
Why?
|
| Thrombin | 2 | 2010 | 147 | 0.150 |
Why?
|
| Ischemic Preconditioning | 1 | 2019 | 40 | 0.150 |
Why?
|
| Models, Statistical | 3 | 2012 | 624 | 0.150 |
Why?
|
| Organizations | 1 | 2019 | 22 | 0.150 |
Why?
|
| Curriculum | 1 | 2005 | 928 | 0.150 |
Why?
|
| Ceruloplasmin | 1 | 2018 | 7 | 0.150 |
Why?
|
| Blood-Brain Barrier | 3 | 2018 | 132 | 0.150 |
Why?
|
| Muscles | 5 | 2004 | 320 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2018 | 851 | 0.150 |
Why?
|
| Prevalence | 9 | 2019 | 2564 | 0.150 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2018 | 36 | 0.150 |
Why?
|
| Stress, Psychological | 1 | 2007 | 1070 | 0.150 |
Why?
|
| Directed Molecular Evolution | 1 | 2018 | 26 | 0.150 |
Why?
|
| Sulfonamides | 2 | 2012 | 497 | 0.150 |
Why?
|
| Laser-Doppler Flowmetry | 3 | 2012 | 33 | 0.150 |
Why?
|
| Vena Cava, Superior | 1 | 2018 | 22 | 0.150 |
Why?
|
| HIV Protease Inhibitors | 2 | 2009 | 68 | 0.150 |
Why?
|
| Haptoglobins | 1 | 2018 | 53 | 0.150 |
Why?
|
| Periodontal Diseases | 4 | 1985 | 61 | 0.150 |
Why?
|
| Triage | 1 | 2000 | 207 | 0.150 |
Why?
|
| Lymphocytosis | 1 | 1998 | 10 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2024 | 1327 | 0.150 |
Why?
|
| Lymphoma, B-Cell | 1 | 2019 | 103 | 0.150 |
Why?
|
| Forests | 1 | 2018 | 58 | 0.150 |
Why?
|
| Cerebellum | 3 | 2016 | 218 | 0.150 |
Why?
|
| Chronic Disease | 4 | 2015 | 1724 | 0.150 |
Why?
|
| Proteoglycans | 1 | 2018 | 109 | 0.150 |
Why?
|
| Microfluidics | 1 | 2018 | 52 | 0.150 |
Why?
|
| Occupational Exposure | 1 | 2021 | 302 | 0.150 |
Why?
|
| Postoperative Complications | 3 | 2015 | 2481 | 0.150 |
Why?
|
| Hindlimb | 3 | 2015 | 126 | 0.140 |
Why?
|
| Monocytes | 3 | 2015 | 554 | 0.140 |
Why?
|
| Excitatory Amino Acid Antagonists | 3 | 2007 | 96 | 0.140 |
Why?
|
| Executive Function | 4 | 2017 | 433 | 0.140 |
Why?
|
| International Classification of Diseases | 1 | 2019 | 122 | 0.140 |
Why?
|
| Autoimmune Diseases | 1 | 2021 | 428 | 0.140 |
Why?
|
| Emergency Medical Services | 2 | 2002 | 522 | 0.140 |
Why?
|
| Counseling | 1 | 2021 | 386 | 0.140 |
Why?
|
| Selegiline | 2 | 2007 | 4 | 0.140 |
Why?
|
| Cerebrovascular Disorders | 1 | 2018 | 90 | 0.140 |
Why?
|
| Single-Blind Method | 2 | 2018 | 271 | 0.140 |
Why?
|
| Perinatal Care | 1 | 2018 | 55 | 0.140 |
Why?
|
| Consensus | 2 | 2017 | 622 | 0.140 |
Why?
|
| Antineoplastic Agents | 3 | 2021 | 2045 | 0.140 |
Why?
|
| MAP Kinase Signaling System | 3 | 2011 | 314 | 0.140 |
Why?
|
| Neurons | 6 | 2011 | 1509 | 0.140 |
Why?
|
| Incidence | 4 | 2021 | 2646 | 0.140 |
Why?
|
| Hearing Aids | 1 | 2019 | 73 | 0.140 |
Why?
|
| Education, Medical | 2 | 2000 | 254 | 0.140 |
Why?
|
| Tears | 1 | 1997 | 28 | 0.140 |
Why?
|
| Health Behavior | 2 | 2021 | 743 | 0.140 |
Why?
|
| Polysomnography | 1 | 2018 | 178 | 0.140 |
Why?
|
| Epilepsy | 2 | 2012 | 322 | 0.140 |
Why?
|
| Friends | 1 | 2018 | 51 | 0.140 |
Why?
|
| Protein Engineering | 1 | 2018 | 106 | 0.140 |
Why?
|
| Luminescent Proteins | 1 | 2018 | 176 | 0.140 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2005 | 399 | 0.140 |
Why?
|
| Infant, Newborn | 7 | 2020 | 5772 | 0.140 |
Why?
|
| Clinical Protocols | 1 | 2019 | 254 | 0.140 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 167 | 0.140 |
Why?
|
| Antiviral Agents | 4 | 2002 | 719 | 0.140 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2017 | 2062 | 0.140 |
Why?
|
| Nitrogen | 1 | 2018 | 162 | 0.140 |
Why?
|
| Administration, Topical | 2 | 2007 | 147 | 0.140 |
Why?
|
| Sjogren's Syndrome | 1 | 1997 | 49 | 0.140 |
Why?
|
| Ambulatory Care | 3 | 2000 | 509 | 0.140 |
Why?
|
| Hemostasis | 2 | 2010 | 80 | 0.140 |
Why?
|
| Middle Cerebral Artery | 4 | 2020 | 43 | 0.140 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 181 | 0.140 |
Why?
|
| Metabolic Diseases | 1 | 1998 | 104 | 0.140 |
Why?
|
| Machine Learning | 1 | 2022 | 441 | 0.140 |
Why?
|
| Acclimatization | 1 | 2018 | 166 | 0.140 |
Why?
|
| Cardiovascular Diseases | 3 | 2018 | 2008 | 0.140 |
Why?
|
| Hydrocortisone | 2 | 2020 | 306 | 0.130 |
Why?
|
| Proteomics | 1 | 2023 | 1058 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2013 | 3630 | 0.130 |
Why?
|
| Peptide T | 1 | 1996 | 1 | 0.130 |
Why?
|
| Patient Positioning | 1 | 2017 | 54 | 0.130 |
Why?
|
| Colorectal Neoplasms | 1 | 2024 | 748 | 0.130 |
Why?
|
| Anger | 1 | 2017 | 56 | 0.130 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2017 | 32 | 0.130 |
Why?
|
| Nutritional Status | 2 | 1999 | 328 | 0.130 |
Why?
|
| Herpesvirus 8, Human | 1 | 2017 | 60 | 0.130 |
Why?
|
| Facial Recognition | 1 | 2017 | 30 | 0.130 |
Why?
|
| Case-Control Studies | 3 | 2021 | 3384 | 0.130 |
Why?
|
| Cerebellopontine Angle | 1 | 1996 | 6 | 0.130 |
Why?
|
| Hordeum | 1 | 1996 | 2 | 0.130 |
Why?
|
| Promoter Regions, Genetic | 2 | 2023 | 1213 | 0.130 |
Why?
|
| Mitochondria, Muscle | 2 | 1995 | 111 | 0.130 |
Why?
|
| Electrocardiography | 3 | 2016 | 613 | 0.130 |
Why?
|
| Facial Paralysis | 1 | 1996 | 17 | 0.130 |
Why?
|
| Facial Expression | 1 | 2017 | 72 | 0.130 |
Why?
|
| Recovery of Function | 4 | 2018 | 645 | 0.130 |
Why?
|
| Haplotypes | 2 | 2015 | 474 | 0.130 |
Why?
|
| Marriage | 1 | 2017 | 116 | 0.130 |
Why?
|
| Facial Nerve | 1 | 1996 | 34 | 0.130 |
Why?
|
| Age Factors | 10 | 2013 | 3161 | 0.130 |
Why?
|
| Environmental Monitoring | 1 | 2018 | 309 | 0.130 |
Why?
|
| Cerebellar Diseases | 2 | 2011 | 23 | 0.130 |
Why?
|
| Imatinib Mesylate | 1 | 2016 | 75 | 0.130 |
Why?
|
| Neurophysiology | 1 | 2016 | 11 | 0.130 |
Why?
|
| Bacopa | 1 | 2015 | 1 | 0.130 |
Why?
|
| Demyelinating Diseases | 2 | 1994 | 84 | 0.130 |
Why?
|
| Erythrocyte Indices | 1 | 2015 | 27 | 0.130 |
Why?
|
| Salvage Therapy | 1 | 2017 | 136 | 0.120 |
Why?
|
| Retrospective Studies | 14 | 2021 | 14553 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2019 | 756 | 0.120 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2018 | 221 | 0.120 |
Why?
|
| Longitudinal Studies | 8 | 2019 | 2724 | 0.120 |
Why?
|
| Postural Balance | 3 | 2018 | 199 | 0.120 |
Why?
|
| Diagnostic Tests, Routine | 1 | 1997 | 104 | 0.120 |
Why?
|
| Calibration | 3 | 2013 | 140 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 528 | 0.120 |
Why?
|
| Air Pollution | 1 | 2018 | 218 | 0.120 |
Why?
|
| Plant Proteins | 1 | 1996 | 89 | 0.120 |
Why?
|
| Logistic Models | 7 | 2015 | 1989 | 0.120 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2018 | 546 | 0.120 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 417 | 0.120 |
Why?
|
| Gingiva | 4 | 1985 | 25 | 0.120 |
Why?
|
| Motor Activity | 2 | 2011 | 684 | 0.120 |
Why?
|
| Lower Body Negative Pressure | 1 | 2015 | 22 | 0.120 |
Why?
|
| Attitude | 1 | 2017 | 254 | 0.120 |
Why?
|
| Low Back Pain | 2 | 2015 | 105 | 0.120 |
Why?
|
| Verbal Learning | 1 | 2015 | 65 | 0.120 |
Why?
|
| Magnetic Resonance Spectroscopy | 5 | 2015 | 541 | 0.120 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2016 | 118 | 0.120 |
Why?
|
| Respiration, Artificial | 2 | 2012 | 617 | 0.120 |
Why?
|
| Tibial Nerve | 4 | 2000 | 9 | 0.120 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2014 | 7 | 0.120 |
Why?
|
| Quality Assurance, Health Care | 1 | 1997 | 318 | 0.120 |
Why?
|
| Transcription, Genetic | 2 | 2024 | 1416 | 0.120 |
Why?
|
| United States | 14 | 2019 | 13913 | 0.120 |
Why?
|
| Retinitis Pigmentosa | 1 | 2014 | 20 | 0.120 |
Why?
|
| Imidazoles | 1 | 2016 | 235 | 0.120 |
Why?
|
| Sleep Wake Disorders | 2 | 2016 | 255 | 0.120 |
Why?
|
| Cerebrum | 1 | 2014 | 6 | 0.120 |
Why?
|
| Pregnancy | 3 | 2020 | 6423 | 0.120 |
Why?
|
| Thigh | 4 | 2017 | 53 | 0.110 |
Why?
|
| Reference Values | 7 | 2014 | 796 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1201 | 0.110 |
Why?
|
| Triterpenes | 1 | 2014 | 20 | 0.110 |
Why?
|
| Stress, Physiological | 1 | 2017 | 412 | 0.110 |
Why?
|
| Phantoms, Imaging | 2 | 2013 | 137 | 0.110 |
Why?
|
| Air Pollutants | 1 | 2018 | 314 | 0.110 |
Why?
|
| Nerve Fibers | 2 | 2007 | 91 | 0.110 |
Why?
|
| Anemia | 1 | 2015 | 162 | 0.110 |
Why?
|
| Rest | 2 | 2007 | 120 | 0.110 |
Why?
|
| Menu Planning | 1 | 1994 | 4 | 0.110 |
Why?
|
| Coinfection | 2 | 2015 | 131 | 0.110 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1997 | 230 | 0.110 |
Why?
|
| Cerebellar Neoplasms | 1 | 1996 | 150 | 0.110 |
Why?
|
| Thoracic Outlet Syndrome | 1 | 1994 | 15 | 0.110 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 900 | 0.110 |
Why?
|
| Creatine Kinase | 4 | 1998 | 75 | 0.110 |
Why?
|
| Child Day Care Centers | 1 | 1994 | 32 | 0.110 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2014 | 171 | 0.110 |
Why?
|
| Interpersonal Relations | 1 | 2017 | 395 | 0.110 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 98 | 0.110 |
Why?
|
| Elbow | 1 | 2014 | 56 | 0.110 |
Why?
|
| Neural Pathways | 2 | 2012 | 301 | 0.110 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2013 | 34 | 0.110 |
Why?
|
| Ultrasonics | 1 | 1994 | 49 | 0.110 |
Why?
|
| Plant Extracts | 1 | 2015 | 198 | 0.110 |
Why?
|
| Epithelial Cells | 1 | 2020 | 1063 | 0.110 |
Why?
|
| Memory | 1 | 2015 | 241 | 0.110 |
Why?
|
| Neurosyphilis | 1 | 2013 | 3 | 0.110 |
Why?
|
| Treponema pallidum | 1 | 2013 | 8 | 0.110 |
Why?
|
| Cloning, Molecular | 4 | 1996 | 524 | 0.110 |
Why?
|
| AIDS-Related Complex | 1 | 1993 | 3 | 0.110 |
Why?
|
| Endpoint Determination | 1 | 2014 | 76 | 0.110 |
Why?
|
| Hypnosis | 1 | 2013 | 6 | 0.100 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 1994 | 104 | 0.100 |
Why?
|
| Mutism | 1 | 2013 | 5 | 0.100 |
Why?
|
| Amyloid beta-Peptides | 1 | 2016 | 211 | 0.100 |
Why?
|
| Neuritis | 3 | 2004 | 3 | 0.100 |
Why?
|
| Endothelial Cells | 1 | 2018 | 749 | 0.100 |
Why?
|
| Tertiary Care Centers | 1 | 2014 | 153 | 0.100 |
Why?
|
| Cholesterol, LDL | 2 | 2014 | 358 | 0.100 |
Why?
|
| Risk | 4 | 2019 | 860 | 0.100 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2015 | 137 | 0.100 |
Why?
|
| Texas | 5 | 1998 | 237 | 0.100 |
Why?
|
| Regional Blood Flow | 2 | 2012 | 463 | 0.100 |
Why?
|
| Venous Thrombosis | 1 | 2015 | 176 | 0.100 |
Why?
|
| Motor Neuron Disease | 1 | 2012 | 16 | 0.100 |
Why?
|
| Glycoproteins | 3 | 1997 | 338 | 0.100 |
Why?
|
| Clinical Medicine | 1 | 2013 | 21 | 0.100 |
Why?
|
| Neurology | 2 | 2012 | 103 | 0.100 |
Why?
|
| Feedback, Physiological | 1 | 2013 | 76 | 0.100 |
Why?
|
| Microcirculation | 2 | 2010 | 145 | 0.100 |
Why?
|
| Voice Disorders | 1 | 1992 | 22 | 0.100 |
Why?
|
| Osteitis | 1 | 2012 | 2 | 0.100 |
Why?
|
| Inflammation | 5 | 2019 | 2748 | 0.100 |
Why?
|
| Breath Holding | 1 | 2012 | 7 | 0.100 |
Why?
|
| Disabled Persons | 1 | 2014 | 138 | 0.100 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2024 | 177 | 0.100 |
Why?
|
| Mycobacterium avium | 1 | 2012 | 21 | 0.100 |
Why?
|
| Dementia | 1 | 2016 | 227 | 0.100 |
Why?
|
| Smoking | 2 | 2010 | 1502 | 0.100 |
Why?
|
| Child, Preschool | 9 | 2015 | 10522 | 0.100 |
Why?
|
| Duloxetine Hydrochloride | 2 | 2013 | 11 | 0.100 |
Why?
|
| Parents | 2 | 2018 | 1319 | 0.100 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 1 | 2012 | 23 | 0.100 |
Why?
|
| Feedback | 1 | 2013 | 163 | 0.100 |
Why?
|
| Antipruritics | 1 | 2012 | 1 | 0.100 |
Why?
|
| New York City | 3 | 2021 | 81 | 0.100 |
Why?
|
| Fingers | 2 | 2012 | 86 | 0.100 |
Why?
|
| Prescription Drug Misuse | 1 | 2012 | 40 | 0.100 |
Why?
|
| Genetic Variation | 2 | 2014 | 937 | 0.100 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2012 | 30 | 0.100 |
Why?
|
| Chi-Square Distribution | 4 | 2015 | 515 | 0.100 |
Why?
|
| Pulmonary Embolism | 1 | 2014 | 212 | 0.100 |
Why?
|
| Glucosyltransferases | 1 | 2011 | 3 | 0.100 |
Why?
|
| Survival Rate | 5 | 2019 | 1872 | 0.100 |
Why?
|
| Foot Diseases | 1 | 2012 | 16 | 0.100 |
Why?
|
| Methadone | 1 | 2013 | 92 | 0.090 |
Why?
|
| Depressive Disorder, Major | 1 | 2016 | 345 | 0.090 |
Why?
|
| Gingivitis | 4 | 2002 | 12 | 0.090 |
Why?
|
| Odds Ratio | 4 | 2019 | 1022 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 753 | 0.090 |
Why?
|
| Cytomegalovirus Infections | 1 | 1994 | 190 | 0.090 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2012 | 42 | 0.090 |
Why?
|
| Fourier Analysis | 3 | 2020 | 39 | 0.090 |
Why?
|
| Drug Eruptions | 2 | 2003 | 27 | 0.090 |
Why?
|
| Wound Healing | 3 | 2010 | 308 | 0.090 |
Why?
|
| Temporal Bone | 1 | 2012 | 49 | 0.090 |
Why?
|
| Hepatitis C Antibodies | 1 | 2011 | 11 | 0.090 |
Why?
|
| Forearm | 1 | 2012 | 117 | 0.090 |
Why?
|
| Carbamates | 1 | 2012 | 47 | 0.090 |
Why?
|
| Medication Adherence | 2 | 2016 | 561 | 0.090 |
Why?
|
| Urination | 2 | 2004 | 44 | 0.090 |
Why?
|
| Oxygen | 3 | 2012 | 916 | 0.090 |
Why?
|
| Teaching | 3 | 2000 | 218 | 0.090 |
Why?
|
| Inhibitory Concentration 50 | 4 | 2013 | 86 | 0.090 |
Why?
|
| Organophosphonates | 1 | 2012 | 92 | 0.090 |
Why?
|
| Sensation | 1 | 1991 | 51 | 0.090 |
Why?
|
| Glycerol | 1 | 2011 | 92 | 0.090 |
Why?
|
| Life Expectancy | 1 | 2011 | 61 | 0.090 |
Why?
|
| Survivors | 1 | 2015 | 464 | 0.090 |
Why?
|
| Cerebral Arteries | 1 | 2012 | 60 | 0.090 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2011 | 70 | 0.090 |
Why?
|
| Vibration | 1 | 1991 | 69 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 486 | 0.090 |
Why?
|
| Azetidines | 1 | 2011 | 40 | 0.090 |
Why?
|
| Macrophages | 3 | 2008 | 1489 | 0.090 |
Why?
|
| Adaptation, Physiological | 2 | 2012 | 521 | 0.090 |
Why?
|
| Chlorambucil | 2 | 2022 | 9 | 0.090 |
Why?
|
| Simvastatin | 1 | 2011 | 60 | 0.090 |
Why?
|
| Chromatography, High Pressure Liquid | 5 | 2013 | 585 | 0.090 |
Why?
|
| Sequence Deletion | 1 | 2011 | 179 | 0.090 |
Why?
|
| Registries | 1 | 2019 | 1903 | 0.090 |
Why?
|
| Patient Compliance | 1 | 2015 | 568 | 0.090 |
Why?
|
| Cupriavidus necator | 1 | 2010 | 4 | 0.090 |
Why?
|
| Vasoconstriction | 1 | 2012 | 199 | 0.090 |
Why?
|
| Codes of Ethics | 1 | 2010 | 17 | 0.090 |
Why?
|
| Capsid Proteins | 1 | 2011 | 90 | 0.090 |
Why?
|
| Q Fever | 1 | 1990 | 6 | 0.090 |
Why?
|
| Zea mays | 1 | 2010 | 42 | 0.090 |
Why?
|
| Dioxygenases | 1 | 2010 | 27 | 0.090 |
Why?
|
| Chromatography, Liquid | 3 | 2012 | 426 | 0.090 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2015 | 306 | 0.090 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2011 | 855 | 0.090 |
Why?
|
| Social Behavior | 1 | 2013 | 286 | 0.090 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 1326 | 0.080 |
Why?
|
| Hospital Mortality | 1 | 2015 | 852 | 0.080 |
Why?
|
| Neurons, Afferent | 2 | 2002 | 101 | 0.080 |
Why?
|
| Family | 1 | 2014 | 646 | 0.080 |
Why?
|
| Protein Kinase C | 1 | 2011 | 262 | 0.080 |
Why?
|
| Pain, Intractable | 1 | 2010 | 10 | 0.080 |
Why?
|
| Choice Behavior | 1 | 2012 | 167 | 0.080 |
Why?
|
| Body Height | 1 | 1991 | 192 | 0.080 |
Why?
|
| Injections, Intravenous | 2 | 2009 | 202 | 0.080 |
Why?
|
| Neuralgia, Postherpetic | 1 | 2010 | 40 | 0.080 |
Why?
|
| Hemorrhage | 1 | 2014 | 680 | 0.080 |
Why?
|
| Dopamine Agents | 1 | 2010 | 16 | 0.080 |
Why?
|
| Tunicamycin | 2 | 1980 | 11 | 0.080 |
Why?
|
| Glucosamine | 2 | 1980 | 13 | 0.080 |
Why?
|
| Reflex, Abnormal | 1 | 2009 | 7 | 0.080 |
Why?
|
| Arabidopsis | 1 | 2010 | 85 | 0.080 |
Why?
|
| Brain Injuries | 2 | 2014 | 466 | 0.080 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 763 | 0.080 |
Why?
|
| Family Health | 1 | 2011 | 198 | 0.080 |
Why?
|
| Disease Progression | 5 | 2019 | 2628 | 0.080 |
Why?
|
| Nerve Growth Factors | 2 | 2007 | 75 | 0.080 |
Why?
|
| Patient Satisfaction | 1 | 2014 | 639 | 0.080 |
Why?
|
| Brain Diseases | 2 | 2005 | 134 | 0.080 |
Why?
|
| Vitamin B 12 | 2 | 2002 | 121 | 0.080 |
Why?
|
| Blood Glucose | 2 | 2016 | 2103 | 0.080 |
Why?
|
| Platelet Count | 1 | 2009 | 82 | 0.080 |
Why?
|
| Anesthesia | 1 | 2012 | 172 | 0.080 |
Why?
|
| Walking | 3 | 2018 | 500 | 0.080 |
Why?
|
| Healthy Volunteers | 2 | 2020 | 201 | 0.080 |
Why?
|
| Depressive Disorder | 1 | 2012 | 367 | 0.080 |
Why?
|
| Recurrence | 3 | 2019 | 1013 | 0.080 |
Why?
|
| Doxorubicin | 3 | 2016 | 329 | 0.080 |
Why?
|
| Methylation | 3 | 2002 | 228 | 0.080 |
Why?
|
| Locomotion | 1 | 2009 | 100 | 0.080 |
Why?
|
| Tandem Mass Spectrometry | 4 | 2013 | 528 | 0.080 |
Why?
|
| Hemostatics | 1 | 2009 | 50 | 0.080 |
Why?
|
| Staining and Labeling | 2 | 2007 | 143 | 0.080 |
Why?
|
| Suicide, Attempted | 2 | 2011 | 356 | 0.070 |
Why?
|
| Anemia, Sickle Cell | 1 | 2012 | 253 | 0.070 |
Why?
|
| Disease-Free Survival | 3 | 2019 | 647 | 0.070 |
Why?
|
| Northern Ireland | 3 | 2014 | 7 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 1997 | 1284 | 0.070 |
Why?
|
| Immunity | 1 | 2009 | 138 | 0.070 |
Why?
|
| Paresthesia | 2 | 2021 | 9 | 0.070 |
Why?
|
| Motor Skills Disorders | 1 | 2008 | 26 | 0.070 |
Why?
|
| DNA-Binding Proteins | 2 | 2014 | 1441 | 0.070 |
Why?
|
| Postmortem Changes | 1 | 2007 | 16 | 0.070 |
Why?
|
| Cholinesterases | 1 | 2007 | 10 | 0.070 |
Why?
|
| Hepacivirus | 3 | 2015 | 242 | 0.070 |
Why?
|
| Qualitative Research | 1 | 2015 | 1235 | 0.070 |
Why?
|
| Normal Distribution | 2 | 2014 | 21 | 0.070 |
Why?
|
| Pressoreceptors | 1 | 1988 | 19 | 0.070 |
Why?
|
| Nerve Degeneration | 2 | 2007 | 47 | 0.070 |
Why?
|
| Azirines | 1 | 1987 | 2 | 0.070 |
Why?
|
| Nafoxidine | 1 | 1987 | 9 | 0.070 |
Why?
|
| Models, Theoretical | 1 | 2011 | 549 | 0.070 |
Why?
|
| Aziridines | 1 | 1987 | 5 | 0.070 |
Why?
|
| Muscular Atrophy | 2 | 2000 | 75 | 0.070 |
Why?
|
| Affinity Labels | 1 | 1987 | 26 | 0.070 |
Why?
|
| Humerus | 1 | 2007 | 41 | 0.070 |
Why?
|
| Cyclohexanols | 1 | 2007 | 12 | 0.070 |
Why?
|
| Neutrophils | 2 | 2001 | 1209 | 0.070 |
Why?
|
| Venlafaxine Hydrochloride | 1 | 2007 | 14 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2011 | 312 | 0.070 |
Why?
|
| Syndrome | 2 | 2018 | 338 | 0.070 |
Why?
|
| Crown Ethers | 2 | 2006 | 4 | 0.070 |
Why?
|
| Observer Variation | 3 | 2007 | 314 | 0.070 |
Why?
|
| Genes | 1 | 1988 | 225 | 0.070 |
Why?
|
| Artificial Intelligence | 2 | 2012 | 245 | 0.070 |
Why?
|
| Transcription Factors | 2 | 2014 | 1645 | 0.070 |
Why?
|
| Cytoprotection | 1 | 2007 | 56 | 0.070 |
Why?
|
| Administration, Buccal | 1 | 2007 | 1 | 0.070 |
Why?
|
| Computers, Handheld | 1 | 2007 | 23 | 0.070 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2007 | 43 | 0.070 |
Why?
|
| Chemokines | 1 | 2008 | 227 | 0.070 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2012 | 353 | 0.070 |
Why?
|
| Sphygmomanometers | 2 | 2017 | 9 | 0.070 |
Why?
|
| S-Adenosylmethionine | 2 | 2004 | 55 | 0.070 |
Why?
|
| Tablets | 1 | 2007 | 35 | 0.070 |
Why?
|
| Pyrrolidines | 1 | 1987 | 69 | 0.070 |
Why?
|
| Ankle | 2 | 2005 | 62 | 0.070 |
Why?
|
| Hot Temperature | 1 | 2009 | 369 | 0.070 |
Why?
|
| Ganglia, Spinal | 1 | 2007 | 75 | 0.070 |
Why?
|
| Viral Proteins | 2 | 1980 | 327 | 0.070 |
Why?
|
| Cyclopropanes | 3 | 2015 | 89 | 0.070 |
Why?
|
| Universities | 2 | 2021 | 409 | 0.070 |
Why?
|
| Fungal Proteins | 2 | 2005 | 130 | 0.070 |
Why?
|
| Behavior Therapy | 1 | 2009 | 241 | 0.070 |
Why?
|
| Alkynes | 3 | 2015 | 56 | 0.070 |
Why?
|
| Antioxidants | 2 | 2007 | 558 | 0.070 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2007 | 93 | 0.070 |
Why?
|
| Embolism, Fat | 1 | 1986 | 11 | 0.070 |
Why?
|
| Homocysteine | 2 | 2004 | 152 | 0.070 |
Why?
|
| Lipopolysaccharide Receptors | 2 | 2011 | 86 | 0.070 |
Why?
|
| Baroreflex | 1 | 2007 | 53 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 1996 | 1708 | 0.060 |
Why?
|
| Blotting, Southern | 4 | 2010 | 70 | 0.060 |
Why?
|
| Gingival Diseases | 2 | 1985 | 20 | 0.060 |
Why?
|
| Neuroprotective Agents | 1 | 2007 | 121 | 0.060 |
Why?
|
| Perchlorates | 1 | 2006 | 4 | 0.060 |
Why?
|
| Malocclusion | 2 | 1985 | 25 | 0.060 |
Why?
|
| Muscle Contraction | 2 | 2008 | 423 | 0.060 |
Why?
|
| Bone Marrow Transplantation | 2 | 2005 | 277 | 0.060 |
Why?
|
| Virus Replication | 3 | 2017 | 453 | 0.060 |
Why?
|
| DNA | 4 | 1990 | 1406 | 0.060 |
Why?
|
| Metabolic Syndrome | 1 | 2009 | 340 | 0.060 |
Why?
|
| Chromatography, Ion Exchange | 1 | 2006 | 52 | 0.060 |
Why?
|
| International Cooperation | 2 | 2019 | 177 | 0.060 |
Why?
|
| Neuromuscular Junction | 2 | 2012 | 58 | 0.060 |
Why?
|
| Gingival Recession | 1 | 1985 | 6 | 0.060 |
Why?
|
| Suicidal Ideation | 1 | 2011 | 493 | 0.060 |
Why?
|
| Polyradiculopathy | 1 | 2005 | 2 | 0.060 |
Why?
|
| Drug Design | 1 | 2007 | 158 | 0.060 |
Why?
|
| Dental Plaque | 4 | 2002 | 17 | 0.060 |
Why?
|
| Oxazines | 1 | 2005 | 28 | 0.060 |
Why?
|
| Muscle Strength | 1 | 2009 | 304 | 0.060 |
Why?
|
| Quadriplegia | 1 | 2005 | 12 | 0.060 |
Why?
|
| Pattern Recognition, Automated | 1 | 2006 | 75 | 0.060 |
Why?
|
| Axons | 1 | 2007 | 193 | 0.060 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2005 | 22 | 0.060 |
Why?
|
| Apoptosis | 1 | 2014 | 2489 | 0.060 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 1985 | 53 | 0.060 |
Why?
|
| Water Supply | 1 | 2006 | 74 | 0.060 |
Why?
|
| beta 2-Microglobulin | 1 | 2005 | 49 | 0.060 |
Why?
|
| Immunization | 2 | 1998 | 411 | 0.060 |
Why?
|
| Primary Health Care | 1 | 2016 | 1687 | 0.060 |
Why?
|
| Periodontitis | 2 | 1982 | 49 | 0.060 |
Why?
|
| Patient Selection | 3 | 2013 | 660 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2011 | 1119 | 0.060 |
Why?
|
| Fluconazole | 1 | 2005 | 18 | 0.060 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2011 | 567 | 0.060 |
Why?
|
| Alveoloplasty | 1 | 1985 | 2 | 0.060 |
Why?
|
| Pyridines | 1 | 2009 | 478 | 0.060 |
Why?
|
| Visual Cortex | 1 | 2006 | 68 | 0.060 |
Why?
|
| Green Fluorescent Proteins | 3 | 2018 | 390 | 0.060 |
Why?
|
| Neuroimaging | 2 | 2018 | 279 | 0.060 |
Why?
|
| Costs and Cost Analysis | 2 | 1997 | 201 | 0.060 |
Why?
|
| United Kingdom | 1 | 2005 | 258 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 1997 | 2104 | 0.060 |
Why?
|
| Stem Cell Transplantation | 2 | 2005 | 166 | 0.060 |
Why?
|
| Weight Loss | 3 | 1996 | 740 | 0.060 |
Why?
|
| Mood Disorders | 1 | 2005 | 121 | 0.060 |
Why?
|
| Socioeconomic Factors | 4 | 2012 | 1214 | 0.060 |
Why?
|
| Kinetics | 3 | 2017 | 1645 | 0.060 |
Why?
|
| Receptors, Estrogen | 1 | 1987 | 422 | 0.060 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2005 | 64 | 0.060 |
Why?
|
| Vincristine | 2 | 2016 | 108 | 0.060 |
Why?
|
| Mycoses | 1 | 2005 | 73 | 0.060 |
Why?
|
| Multiple Sclerosis | 1 | 2010 | 438 | 0.060 |
Why?
|
| Glucose | 1 | 2010 | 1003 | 0.060 |
Why?
|
| Cyclophosphamide | 2 | 2016 | 234 | 0.060 |
Why?
|
| Survival Analysis | 4 | 2015 | 1271 | 0.060 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2004 | 21 | 0.060 |
Why?
|
| Antifungal Agents | 1 | 2005 | 130 | 0.060 |
Why?
|
| Brain Chemistry | 1 | 2004 | 118 | 0.060 |
Why?
|
| Asymptomatic Diseases | 2 | 2016 | 84 | 0.060 |
Why?
|
| Fracture Healing | 1 | 2004 | 75 | 0.060 |
Why?
|
| Communication | 2 | 2010 | 847 | 0.050 |
Why?
|
| Lipoproteins | 1 | 2005 | 172 | 0.050 |
Why?
|
| Swine | 3 | 2012 | 761 | 0.050 |
Why?
|
| Brachial Plexus | 2 | 1994 | 28 | 0.050 |
Why?
|
| Base Sequence | 6 | 1996 | 2142 | 0.050 |
Why?
|
| Cell Differentiation | 3 | 2020 | 1900 | 0.050 |
Why?
|
| Biopsy | 5 | 1999 | 1089 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 1199 | 0.050 |
Why?
|
| Bone Transplantation | 1 | 2004 | 84 | 0.050 |
Why?
|
| Bone Plates | 1 | 2004 | 75 | 0.050 |
Why?
|
| Carrier Proteins | 2 | 1998 | 741 | 0.050 |
Why?
|
| Amines | 1 | 2003 | 37 | 0.050 |
Why?
|
| Prostheses and Implants | 1 | 1985 | 135 | 0.050 |
Why?
|
| Cations | 1 | 2003 | 80 | 0.050 |
Why?
|
| Phagocytosis | 2 | 2001 | 362 | 0.050 |
Why?
|
| Random Allocation | 4 | 2010 | 347 | 0.050 |
Why?
|
| Laryngeal Muscles | 2 | 1993 | 6 | 0.050 |
Why?
|
| Binding Sites | 2 | 2023 | 1251 | 0.050 |
Why?
|
| Interferons | 1 | 2024 | 189 | 0.050 |
Why?
|
| Peptides, Cyclic | 1 | 2005 | 256 | 0.050 |
Why?
|
| Sex Factors | 5 | 2008 | 1973 | 0.050 |
Why?
|
| Microscopy, Electron | 3 | 1995 | 425 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2024 | 393 | 0.050 |
Why?
|
| Learning | 2 | 2017 | 403 | 0.050 |
Why?
|
| Blotting, Western | 3 | 2010 | 1204 | 0.050 |
Why?
|
| Bone Screws | 1 | 2004 | 113 | 0.050 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2004 | 165 | 0.050 |
Why?
|
| Molecular Sequence Data | 5 | 2011 | 2833 | 0.050 |
Why?
|
| Salivary Proteins and Peptides | 1 | 2002 | 14 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2024 | 3185 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2017 | 1282 | 0.050 |
Why?
|
| Creatine | 2 | 2018 | 58 | 0.050 |
Why?
|
| Societies, Medical | 2 | 2012 | 759 | 0.050 |
Why?
|
| Somatosensory Cortex | 1 | 1983 | 36 | 0.050 |
Why?
|
| Liver | 2 | 2014 | 1839 | 0.050 |
Why?
|
| Metals | 1 | 2003 | 123 | 0.050 |
Why?
|
| Carcinogenesis | 1 | 2024 | 214 | 0.050 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2002 | 41 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2023 | 870 | 0.050 |
Why?
|
| Memory, Short-Term | 2 | 2018 | 258 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2007 | 430 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 2511 | 0.050 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2002 | 77 | 0.050 |
Why?
|
| Mental Disorders | 2 | 2014 | 1035 | 0.050 |
Why?
|
| Internship and Residency | 2 | 2006 | 1058 | 0.050 |
Why?
|
| Cytokines | 2 | 2008 | 2022 | 0.050 |
Why?
|
| Treatment Failure | 3 | 2013 | 339 | 0.050 |
Why?
|
| San Francisco | 1 | 2002 | 51 | 0.050 |
Why?
|
| Gene Expression | 3 | 2016 | 1465 | 0.050 |
Why?
|
| Neoplasms | 3 | 2013 | 2454 | 0.050 |
Why?
|
| Vitamin B 6 | 1 | 2021 | 9 | 0.050 |
Why?
|
| HEK293 Cells | 1 | 2024 | 697 | 0.050 |
Why?
|
| Gene Regulatory Networks | 1 | 2024 | 280 | 0.050 |
Why?
|
| Dyspnea | 1 | 2004 | 239 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2024 | 374 | 0.050 |
Why?
|
| Blood Component Removal | 1 | 2002 | 26 | 0.050 |
Why?
|
| Occipital Lobe | 1 | 2001 | 23 | 0.050 |
Why?
|
| Pyridoxine | 1 | 2021 | 32 | 0.050 |
Why?
|
| Choline | 2 | 2018 | 122 | 0.050 |
Why?
|
| Health Care Surveys | 2 | 2001 | 558 | 0.050 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2002 | 70 | 0.050 |
Why?
|
| Tissue Donors | 1 | 2004 | 391 | 0.050 |
Why?
|
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2001 | 5 | 0.050 |
Why?
|
| Flow Cytometry | 3 | 2018 | 1160 | 0.050 |
Why?
|
| Macrophage-1 Antigen | 1 | 2001 | 28 | 0.050 |
Why?
|
| Leg | 1 | 2003 | 240 | 0.040 |
Why?
|
| Weed Control | 1 | 2020 | 1 | 0.040 |
Why?
|
| Plant Weeds | 1 | 2020 | 4 | 0.040 |
Why?
|
| Epidermis | 1 | 2002 | 155 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2005 | 583 | 0.040 |
Why?
|
| Software | 2 | 2017 | 608 | 0.040 |
Why?
|
| Periodontal Index | 4 | 2002 | 13 | 0.040 |
Why?
|
| Secretory Vesicles | 1 | 2020 | 24 | 0.040 |
Why?
|
| Crops, Agricultural | 1 | 2020 | 29 | 0.040 |
Why?
|
| Newcastle disease virus | 1 | 1980 | 17 | 0.040 |
Why?
|
| Partial Pressure | 1 | 2000 | 30 | 0.040 |
Why?
|
| Genes, Reporter | 2 | 2004 | 266 | 0.040 |
Why?
|
| Loss of Heterozygosity | 1 | 2000 | 45 | 0.040 |
Why?
|
| Sciatic Nerve | 1 | 2000 | 57 | 0.040 |
Why?
|
| Paraparesis | 1 | 2000 | 6 | 0.040 |
Why?
|
| Signal Detection, Psychological | 1 | 2000 | 24 | 0.040 |
Why?
|
| Protein Binding | 3 | 2013 | 2123 | 0.040 |
Why?
|
| Immunohistochemistry | 3 | 2005 | 1690 | 0.040 |
Why?
|
| Neurosurgery | 1 | 1980 | 35 | 0.040 |
Why?
|
| Cations, Divalent | 1 | 2020 | 53 | 0.040 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2001 | 135 | 0.040 |
Why?
|
| Nerve Growth Factor | 1 | 2000 | 27 | 0.040 |
Why?
|
| Disease Models, Animal | 3 | 2014 | 4077 | 0.040 |
Why?
|
| Models, Educational | 2 | 1997 | 91 | 0.040 |
Why?
|
| Salmon | 2 | 2010 | 22 | 0.040 |
Why?
|
| Prolactin | 1 | 2020 | 97 | 0.040 |
Why?
|
| Mice | 5 | 2023 | 16983 | 0.040 |
Why?
|
| Exanthema | 1 | 2000 | 74 | 0.040 |
Why?
|
| Artifacts | 1 | 2000 | 127 | 0.040 |
Why?
|
| Cardiac Catheterization | 1 | 2023 | 520 | 0.040 |
Why?
|
| Drug Combinations | 2 | 2013 | 331 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2000 | 137 | 0.040 |
Why?
|
| Biological Evolution | 1 | 2023 | 435 | 0.040 |
Why?
|
| Ulcer | 1 | 1999 | 28 | 0.040 |
Why?
|
| Synaptic Transmission | 3 | 1992 | 275 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2020 | 541 | 0.040 |
Why?
|
| Esophageal Diseases | 1 | 1999 | 27 | 0.040 |
Why?
|
| Neuroprotection | 1 | 2019 | 39 | 0.040 |
Why?
|
| RNA, Messenger | 5 | 2004 | 2703 | 0.040 |
Why?
|
| Immunization Programs | 1 | 2001 | 214 | 0.040 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2019 | 38 | 0.040 |
Why?
|
| Macaca fascicularis | 1 | 1999 | 63 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2019 | 193 | 0.040 |
Why?
|
| Animals, Laboratory | 1 | 1999 | 17 | 0.040 |
Why?
|
| Mexiletine | 1 | 1998 | 6 | 0.040 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 1998 | 14 | 0.040 |
Why?
|
| Length of Stay | 1 | 2004 | 1133 | 0.040 |
Why?
|
| Vesicular stomatitis Indiana virus | 1 | 1978 | 13 | 0.040 |
Why?
|
| Muscle Hypotonia | 1 | 2018 | 31 | 0.040 |
Why?
|
| Amitriptyline | 1 | 1998 | 20 | 0.040 |
Why?
|
| Ebolavirus | 1 | 1999 | 34 | 0.040 |
Why?
|
| Proprioception | 2 | 2009 | 26 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2024 | 804 | 0.040 |
Why?
|
| Pituitary Neoplasms | 1 | 2000 | 180 | 0.040 |
Why?
|
| Motor Skills | 2 | 2011 | 93 | 0.040 |
Why?
|
| Nimodipine | 1 | 1998 | 8 | 0.040 |
Why?
|
| Self Efficacy | 1 | 2022 | 377 | 0.040 |
Why?
|
| Japan | 1 | 2018 | 98 | 0.040 |
Why?
|
| Clinical Competence | 1 | 2006 | 1020 | 0.040 |
Why?
|
| Acculturation | 1 | 1998 | 51 | 0.040 |
Why?
|
| Vacuoles | 1 | 1998 | 36 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2001 | 412 | 0.040 |
Why?
|
| Optics and Photonics | 1 | 2018 | 43 | 0.040 |
Why?
|
| Erectile Dysfunction | 1 | 1998 | 39 | 0.040 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2001 | 348 | 0.040 |
Why?
|
| Electronics | 1 | 2018 | 74 | 0.040 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 1998 | 112 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 836 | 0.040 |
Why?
|
| Rats | 4 | 2018 | 5487 | 0.040 |
Why?
|
| Trees | 1 | 2018 | 69 | 0.040 |
Why?
|
| Myocarditis | 1 | 2019 | 98 | 0.040 |
Why?
|
| Cytarabine | 1 | 1998 | 57 | 0.040 |
Why?
|
| Fluorescence | 1 | 2018 | 156 | 0.040 |
Why?
|
| Gene Expression Regulation, Fungal | 2 | 2011 | 68 | 0.040 |
Why?
|
| Receptors, Somatotropin | 1 | 1997 | 9 | 0.040 |
Why?
|
| China | 1 | 2018 | 192 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2015 | 1269 | 0.040 |
Why?
|
| Age Distribution | 1 | 1999 | 372 | 0.040 |
Why?
|
| Cellular Reprogramming | 1 | 2018 | 95 | 0.040 |
Why?
|
| Cardiac Output | 1 | 2018 | 157 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2000 | 581 | 0.040 |
Why?
|
| Fatigue | 2 | 2014 | 319 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2018 | 179 | 0.040 |
Why?
|
| New York | 1 | 1998 | 128 | 0.040 |
Why?
|
| Keratoconjunctivitis Sicca | 1 | 1997 | 5 | 0.040 |
Why?
|
| Europe | 1 | 2018 | 363 | 0.040 |
Why?
|
| Myofibrils | 1 | 1998 | 49 | 0.040 |
Why?
|
| Organ Size | 1 | 2018 | 456 | 0.030 |
Why?
|
| Puerto Rico | 1 | 2017 | 52 | 0.030 |
Why?
|
| Expectorants | 1 | 1997 | 24 | 0.030 |
Why?
|
| Infant Mortality | 1 | 2018 | 106 | 0.030 |
Why?
|
| Growth Hormone | 1 | 1997 | 100 | 0.030 |
Why?
|
| Infusions, Intravenous | 2 | 2014 | 402 | 0.030 |
Why?
|
| Calcium Channel Blockers | 1 | 1998 | 161 | 0.030 |
Why?
|
| Cell Separation | 1 | 2018 | 316 | 0.030 |
Why?
|
| Growth Disorders | 1 | 1997 | 81 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2014 | 1205 | 0.030 |
Why?
|
| Dermatitis, Atopic | 1 | 2001 | 319 | 0.030 |
Why?
|
| Polymorphism, Genetic | 2 | 2000 | 636 | 0.030 |
Why?
|
| Purkinje Cells | 1 | 1998 | 71 | 0.030 |
Why?
|
| Physician Executives | 1 | 1997 | 33 | 0.030 |
Why?
|
| Quinazolinones | 1 | 2017 | 19 | 0.030 |
Why?
|
| Anabolic Agents | 1 | 1996 | 12 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 1998 | 128 | 0.030 |
Why?
|
| Mexico | 1 | 2017 | 191 | 0.030 |
Why?
|
| Sampling Studies | 1 | 1997 | 96 | 0.030 |
Why?
|
| Oxandrolone | 1 | 1996 | 8 | 0.030 |
Why?
|
| Clozapine | 1 | 1996 | 21 | 0.030 |
Why?
|
| Psychoses, Substance-Induced | 1 | 1996 | 14 | 0.030 |
Why?
|
| Vital Signs | 1 | 2017 | 41 | 0.030 |
Why?
|
| Papanicolaou Test | 1 | 1997 | 42 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2018 | 611 | 0.030 |
Why?
|
| Medical History Taking | 1 | 1997 | 118 | 0.030 |
Why?
|
| Vaginal Smears | 1 | 1997 | 55 | 0.030 |
Why?
|
| Functional Laterality | 1 | 2017 | 221 | 0.030 |
Why?
|
| Genomics | 1 | 2022 | 716 | 0.030 |
Why?
|
| Acetylcysteine | 1 | 1997 | 146 | 0.030 |
Why?
|
| Somatomedins | 1 | 1996 | 26 | 0.030 |
Why?
|
| Medical Records | 1 | 1997 | 171 | 0.030 |
Why?
|
| Blinking | 1 | 1996 | 8 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 2 | 2012 | 844 | 0.030 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 1996 | 26 | 0.030 |
Why?
|
| Philadelphia Chromosome | 1 | 2016 | 18 | 0.030 |
Why?
|
| Glucuronidase | 1 | 1996 | 44 | 0.030 |
Why?
|
| Organizational Innovation | 1 | 1997 | 139 | 0.030 |
Why?
|
| Patient Safety | 1 | 2019 | 291 | 0.030 |
Why?
|
| Bacteria | 1 | 1982 | 814 | 0.030 |
Why?
|
| Antigens, CD | 3 | 2007 | 487 | 0.030 |
Why?
|
| Erythrocyte Count | 1 | 2015 | 19 | 0.030 |
Why?
|
| Internationality | 1 | 2017 | 150 | 0.030 |
Why?
|
| Language | 1 | 2019 | 283 | 0.030 |
Why?
|
| Cerebral Ventricles | 1 | 2016 | 50 | 0.030 |
Why?
|
| Sural Nerve | 2 | 2007 | 19 | 0.030 |
Why?
|
| Glutens | 1 | 1996 | 57 | 0.030 |
Why?
|
| Gene Expression Regulation, Plant | 1 | 1996 | 55 | 0.030 |
Why?
|
| Ear, Inner | 1 | 1996 | 45 | 0.030 |
Why?
|
| Oculomotor Muscles | 1 | 1996 | 38 | 0.030 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2016 | 69 | 0.030 |
Why?
|
| Clinical Clerkship | 1 | 1997 | 96 | 0.030 |
Why?
|
| Muscular Dystrophies | 1 | 1996 | 35 | 0.030 |
Why?
|
| Saccades | 1 | 1996 | 39 | 0.030 |
Why?
|
| Purines | 1 | 2017 | 172 | 0.030 |
Why?
|
| Robotics | 1 | 2017 | 92 | 0.030 |
Why?
|
| Goals | 1 | 1997 | 163 | 0.030 |
Why?
|
| Mammography | 1 | 1997 | 146 | 0.030 |
Why?
|
| Patients | 1 | 1997 | 169 | 0.030 |
Why?
|
| Wrist Joint | 1 | 1996 | 64 | 0.030 |
Why?
|
| Zalcitabine | 1 | 1995 | 2 | 0.030 |
Why?
|
| Elbow Joint | 1 | 1996 | 67 | 0.030 |
Why?
|
| Stavudine | 1 | 1995 | 8 | 0.030 |
Why?
|
| Poverty Areas | 1 | 1995 | 35 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 1997 | 310 | 0.030 |
Why?
|
| Gait | 1 | 2018 | 280 | 0.030 |
Why?
|
| Immunosorbent Techniques | 1 | 1995 | 20 | 0.030 |
Why?
|
| Acetaminophen | 1 | 1998 | 248 | 0.030 |
Why?
|
| Documentation | 1 | 1997 | 185 | 0.030 |
Why?
|
| Attitude to Health | 1 | 1998 | 433 | 0.030 |
Why?
|
| Personal Satisfaction | 1 | 1997 | 204 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 1997 | 281 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 1995 | 148 | 0.030 |
Why?
|
| HIV Antibodies | 1 | 1995 | 57 | 0.030 |
Why?
|
| Hospitals, Public | 1 | 2015 | 26 | 0.030 |
Why?
|
| DNA Primers | 1 | 1996 | 508 | 0.030 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2015 | 137 | 0.030 |
Why?
|
| Bias | 1 | 1996 | 197 | 0.030 |
Why?
|
| Thioacetamide | 1 | 2014 | 2 | 0.030 |
Why?
|
| Program Development | 1 | 1997 | 355 | 0.030 |
Why?
|
| Heat Shock Transcription Factors | 1 | 2014 | 19 | 0.030 |
Why?
|
| Serologic Tests | 1 | 2014 | 52 | 0.030 |
Why?
|
| Health Surveys | 1 | 1997 | 495 | 0.030 |
Why?
|
| Iron Regulatory Protein 1 | 1 | 2014 | 2 | 0.030 |
Why?
|
| Nutrition Assessment | 1 | 1995 | 86 | 0.030 |
Why?
|
| Myasthenia Gravis | 1 | 1995 | 20 | 0.030 |
Why?
|
| GATA4 Transcription Factor | 1 | 2014 | 18 | 0.030 |
Why?
|
| Pentacyclic Triterpenes | 1 | 2014 | 15 | 0.030 |
Why?
|
| Clinical Audit | 1 | 2014 | 11 | 0.030 |
Why?
|
| Insecta | 1 | 2015 | 63 | 0.030 |
Why?
|
| GTP-Binding Protein beta Subunits | 2 | 2004 | 11 | 0.030 |
Why?
|
| Insurance, Health | 1 | 1997 | 269 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2014 | 79 | 0.030 |
Why?
|
| Anthropometry | 1 | 1995 | 204 | 0.030 |
Why?
|
| Pathology, Molecular | 1 | 2014 | 25 | 0.030 |
Why?
|
| Glutathione Transferase | 2 | 2005 | 102 | 0.030 |
Why?
|
| HIV Seroprevalence | 1 | 1994 | 3 | 0.030 |
Why?
|
| Biomechanical Phenomena | 2 | 2009 | 766 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 1997 | 569 | 0.030 |
Why?
|
| Multidetector Computed Tomography | 1 | 2014 | 33 | 0.030 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 2014 | 6 | 0.030 |
Why?
|
| Sex Work | 1 | 1994 | 21 | 0.030 |
Why?
|
| Food Services | 1 | 1994 | 19 | 0.030 |
Why?
|
| Alopecia | 1 | 2014 | 30 | 0.030 |
Why?
|
| Sound Spectrography | 1 | 1994 | 19 | 0.030 |
Why?
|
| Microcomputers | 1 | 1994 | 15 | 0.030 |
Why?
|
| Faculty, Medical | 1 | 1997 | 269 | 0.030 |
Why?
|
| Escherichia coli | 2 | 2010 | 766 | 0.030 |
Why?
|
| Cerebral Infarction | 1 | 1994 | 42 | 0.030 |
Why?
|
| Liver Failure | 1 | 2014 | 91 | 0.030 |
Why?
|
| Heat-Shock Proteins | 1 | 2014 | 136 | 0.030 |
Why?
|
| Hoarseness | 1 | 1993 | 4 | 0.030 |
Why?
|
| Fires | 1 | 2015 | 87 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2014 | 257 | 0.030 |
Why?
|
| Laryngeal Nerves | 1 | 1993 | 6 | 0.030 |
Why?
|
| Body Mass Index | 2 | 2014 | 2274 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 2014 | 205 | 0.030 |
Why?
|
| Angiography | 1 | 2014 | 197 | 0.030 |
Why?
|
| Nutritional Requirements | 1 | 1994 | 77 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 954 | 0.030 |
Why?
|
| Sanitation | 1 | 1994 | 52 | 0.030 |
Why?
|
| Fluorescent Treponemal Antibody-Absorption Test | 1 | 2013 | 1 | 0.030 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2013 | 4 | 0.030 |
Why?
|
| Plasmids | 2 | 2005 | 360 | 0.030 |
Why?
|
| Nausea | 1 | 2014 | 111 | 0.030 |
Why?
|
| Papio | 1 | 1973 | 91 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 357 | 0.030 |
Why?
|
| Ecosystem | 1 | 2018 | 561 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2004 | 22 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 886 | 0.030 |
Why?
|
| Vomiting | 1 | 2014 | 129 | 0.030 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 1995 | 203 | 0.030 |
Why?
|
| Tic Disorders | 1 | 2013 | 7 | 0.030 |
Why?
|
| HTLV-I Infections | 1 | 1993 | 22 | 0.030 |
Why?
|
| Dental Plaque Index | 2 | 2002 | 4 | 0.030 |
Why?
|
| Cholinergic Antagonists | 1 | 2013 | 29 | 0.030 |
Why?
|
| Blood Proteins | 1 | 1995 | 245 | 0.030 |
Why?
|
| Ultracentrifugation | 1 | 2013 | 48 | 0.030 |
Why?
|
| Genes, pol | 1 | 2012 | 7 | 0.030 |
Why?
|
| Dystonia | 1 | 2013 | 23 | 0.030 |
Why?
|
| Drug Monitoring | 2 | 2009 | 216 | 0.030 |
Why?
|
| Ultrafiltration | 1 | 2012 | 28 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 395 | 0.030 |
Why?
|
| Program Evaluation | 1 | 1997 | 878 | 0.030 |
Why?
|
| Darunavir | 1 | 2012 | 18 | 0.030 |
Why?
|
| Polyradiculoneuropathy | 1 | 1992 | 3 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2014 | 224 | 0.020 |
Why?
|
| Food Preferences | 1 | 1994 | 116 | 0.020 |
Why?
|
| Group Processes | 1 | 2013 | 57 | 0.020 |
Why?
|
| Human Immunodeficiency Virus Proteins | 1 | 2012 | 6 | 0.020 |
Why?
|
| Food | 1 | 1994 | 156 | 0.020 |
Why?
|
| Students, Medical | 1 | 1997 | 323 | 0.020 |
Why?
|
| Cerebral Angiography | 1 | 2012 | 108 | 0.020 |
Why?
|
| Myocardium | 1 | 1998 | 983 | 0.020 |
Why?
|
| Enzyme Activation | 2 | 2004 | 813 | 0.020 |
Why?
|
| Isotope Labeling | 1 | 2013 | 74 | 0.020 |
Why?
|
| Hemoglobin, Sickle | 1 | 2012 | 18 | 0.020 |
Why?
|
| Mothers | 1 | 1998 | 731 | 0.020 |
Why?
|
| World Health Organization | 1 | 2013 | 110 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 369 | 0.020 |
Why?
|
| Laryngoscopy | 1 | 1993 | 100 | 0.020 |
Why?
|
| Eating | 1 | 1995 | 372 | 0.020 |
Why?
|
| Urine | 1 | 2012 | 60 | 0.020 |
Why?
|
| Sexual Partners | 1 | 1994 | 185 | 0.020 |
Why?
|
| Cells, Cultured | 5 | 2007 | 4102 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2013 | 143 | 0.020 |
Why?
|
| Community Health Services | 1 | 1994 | 229 | 0.020 |
Why?
|
| Physical Stimulation | 1 | 2012 | 75 | 0.020 |
Why?
|
| Viral Tropism | 1 | 2012 | 29 | 0.020 |
Why?
|
| Philadelphia | 1 | 2012 | 47 | 0.020 |
Why?
|
| Student Health Services | 1 | 2012 | 15 | 0.020 |
Why?
|
| Nerve Block | 1 | 2013 | 68 | 0.020 |
Why?
|
| HN Protein | 1 | 2011 | 5 | 0.020 |
Why?
|
| Chicago | 1 | 2012 | 57 | 0.020 |
Why?
|
| Furans | 1 | 2012 | 23 | 0.020 |
Why?
|
| Nitriles | 1 | 2013 | 169 | 0.020 |
Why?
|
| T-Lymphocytes | 2 | 1990 | 1937 | 0.020 |
Why?
|
| Safety | 1 | 1994 | 335 | 0.020 |
Why?
|
| Genetic Heterogeneity | 1 | 2012 | 58 | 0.020 |
Why?
|
| Cell Membrane | 3 | 2005 | 734 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2012 | 359 | 0.020 |
Why?
|
| Sensory Thresholds | 1 | 1991 | 32 | 0.020 |
Why?
|
| Task Performance and Analysis | 1 | 2012 | 173 | 0.020 |
Why?
|
| Academies and Institutes | 1 | 2012 | 50 | 0.020 |
Why?
|
| Specimen Handling | 1 | 2012 | 163 | 0.020 |
Why?
|
| Methods | 1 | 1991 | 64 | 0.020 |
Why?
|
| Ezetimibe | 1 | 2011 | 25 | 0.020 |
Why?
|
| Circadian Rhythm | 1 | 2015 | 416 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 211 | 0.020 |
Why?
|
| Face | 1 | 2013 | 165 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 2011 | 89 | 0.020 |
Why?
|
| Cell Survival | 1 | 2014 | 1086 | 0.020 |
Why?
|
| Equipment Design | 1 | 2013 | 514 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2011 | 215 | 0.020 |
Why?
|
| Myositis | 1 | 1991 | 51 | 0.020 |
Why?
|
| Area Under Curve | 2 | 2005 | 306 | 0.020 |
Why?
|
| Ethylene Oxide | 1 | 1990 | 1 | 0.020 |
Why?
|
| Delftia acidovorans | 1 | 2010 | 2 | 0.020 |
Why?
|
| Transformation, Genetic | 1 | 2010 | 14 | 0.020 |
Why?
|
| Space-Time Clustering | 1 | 1990 | 3 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 2011 | 154 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2011 | 331 | 0.020 |
Why?
|
| Observation | 1 | 2010 | 51 | 0.020 |
Why?
|
| Sphingomonadaceae | 1 | 2010 | 13 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2011 | 152 | 0.020 |
Why?
|
| Verbal Behavior | 1 | 2011 | 46 | 0.020 |
Why?
|
| Cardiomyopathies | 1 | 2014 | 340 | 0.020 |
Why?
|
| Hypolipidemic Agents | 1 | 2011 | 92 | 0.020 |
Why?
|
| Occupations | 1 | 1990 | 42 | 0.020 |
Why?
|
| Lesch-Nyhan Syndrome | 1 | 1990 | 3 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 2545 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2014 | 724 | 0.020 |
Why?
|
| Isometric Contraction | 1 | 2012 | 187 | 0.020 |
Why?
|
| Atrophy | 3 | 1999 | 170 | 0.020 |
Why?
|
| Tenofovir | 1 | 2012 | 232 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2011 | 284 | 0.020 |
Why?
|
| Lung Diseases | 1 | 2017 | 743 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2012 | 397 | 0.020 |
Why?
|
| Immunocompetence | 1 | 2010 | 42 | 0.020 |
Why?
|
| Advisory Committees | 1 | 2012 | 216 | 0.020 |
Why?
|
| Physical Examination | 1 | 1991 | 234 | 0.020 |
Why?
|
| Carcinogens | 1 | 1990 | 109 | 0.020 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2011 | 109 | 0.020 |
Why?
|
| Genetic Engineering | 1 | 2010 | 87 | 0.020 |
Why?
|
| Rural Population | 1 | 1994 | 521 | 0.020 |
Why?
|
| Remission Induction | 1 | 2010 | 274 | 0.020 |
Why?
|
| Transgenes | 1 | 2010 | 178 | 0.020 |
Why?
|
| Natalizumab | 1 | 2010 | 40 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2010 | 371 | 0.020 |
Why?
|
| Glycine | 1 | 2010 | 166 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2010 | 287 | 0.020 |
Why?
|
| Lung | 1 | 2022 | 3940 | 0.020 |
Why?
|
| Biological Clocks | 1 | 2009 | 40 | 0.020 |
Why?
|
| Patient Care | 1 | 2010 | 108 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2011 | 189 | 0.020 |
Why?
|
| Actins | 2 | 2005 | 410 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2010 | 187 | 0.020 |
Why?
|
| Informed Consent | 1 | 2010 | 165 | 0.020 |
Why?
|
| Dermatitis, Contact | 1 | 2009 | 17 | 0.020 |
Why?
|
| Mutagens | 1 | 1989 | 17 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2010 | 483 | 0.020 |
Why?
|
| Global Health | 1 | 2012 | 329 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2012 | 778 | 0.020 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2009 | 170 | 0.020 |
Why?
|
| Formaldehyde | 1 | 1989 | 59 | 0.020 |
Why?
|
| Oral Hygiene | 2 | 1982 | 16 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2012 | 332 | 0.020 |
Why?
|
| School Health Services | 1 | 2012 | 234 | 0.020 |
Why?
|
| Back Pain | 1 | 2009 | 53 | 0.020 |
Why?
|
| Atazanavir Sulfate | 1 | 2009 | 41 | 0.020 |
Why?
|
| Conflict of Interest | 1 | 2010 | 123 | 0.020 |
Why?
|
| Reflex, Stretch | 1 | 2008 | 10 | 0.020 |
Why?
|
| Blotting, Northern | 2 | 2004 | 196 | 0.020 |
Why?
|
| Hemostatic Techniques | 1 | 2009 | 45 | 0.020 |
Why?
|
| Nucleic Acid Conformation | 1 | 2012 | 706 | 0.020 |
Why?
|
| Anesthesia, Epidural | 1 | 1988 | 5 | 0.020 |
Why?
|
| Hyperhidrosis | 1 | 2008 | 4 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2010 | 199 | 0.020 |
Why?
|
| Employment | 1 | 2010 | 167 | 0.020 |
Why?
|
| Fibroblasts | 1 | 1973 | 954 | 0.020 |
Why?
|
| Opportunistic Infections | 1 | 1988 | 46 | 0.020 |
Why?
|
| Bupivacaine | 1 | 1988 | 31 | 0.020 |
Why?
|
| Epithelium | 1 | 2009 | 311 | 0.020 |
Why?
|
| Data Collection | 1 | 1991 | 653 | 0.020 |
Why?
|
| Heroin | 1 | 1988 | 30 | 0.020 |
Why?
|
| Preceptorship | 2 | 2000 | 63 | 0.020 |
Why?
|
| Seasons | 1 | 1990 | 493 | 0.020 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2008 | 36 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2009 | 265 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1991 | 532 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1988 | 188 | 0.020 |
Why?
|
| Chromans | 1 | 2007 | 24 | 0.020 |
Why?
|
| HIV Core Protein p24 | 1 | 2007 | 31 | 0.020 |
Why?
|
| Visual Perception | 1 | 2009 | 163 | 0.020 |
Why?
|
| Gene Amplification | 1 | 1988 | 103 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 2057 | 0.020 |
Why?
|
| Spectrum Analysis | 1 | 1988 | 89 | 0.020 |
Why?
|
| Indicators and Reagents | 1 | 1987 | 109 | 0.020 |
Why?
|
| Lithium | 1 | 1987 | 37 | 0.020 |
Why?
|
| Leukocyte Count | 2 | 2001 | 326 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 1987 | 206 | 0.020 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2007 | 67 | 0.020 |
Why?
|
| Receptors, CCR5 | 1 | 2007 | 57 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2011 | 423 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2007 | 59 | 0.020 |
Why?
|
| Monkey Diseases | 2 | 1999 | 20 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2014 | 1021 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2007 | 110 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2007 | 83 | 0.020 |
Why?
|
| Accidental Falls | 1 | 2009 | 169 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2007 | 91 | 0.020 |
Why?
|
| Alveolar Process | 2 | 1985 | 5 | 0.020 |
Why?
|
| Cytosol | 1 | 1987 | 219 | 0.020 |
Why?
|
| Nitrous Oxide | 1 | 1986 | 32 | 0.020 |
Why?
|
| Connective Tissue | 2 | 1985 | 37 | 0.020 |
Why?
|
| Students | 1 | 2012 | 582 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2009 | 471 | 0.020 |
Why?
|
| Chlorides | 1 | 1987 | 139 | 0.020 |
Why?
|
| Sodium Compounds | 1 | 2006 | 4 | 0.020 |
Why?
|
| Ethers, Cyclic | 1 | 2006 | 7 | 0.020 |
Why?
|
| Schiff Bases | 1 | 2006 | 7 | 0.020 |
Why?
|
| Uterus | 1 | 1987 | 207 | 0.020 |
Why?
|
| Nova Scotia | 1 | 2006 | 7 | 0.020 |
Why?
|
| United States Environmental Protection Agency | 1 | 2006 | 24 | 0.020 |
Why?
|
| Chin | 1 | 1985 | 5 | 0.020 |
Why?
|
| Bicuspid | 1 | 1985 | 17 | 0.020 |
Why?
|
| Lymphocytes | 1 | 1988 | 377 | 0.020 |
Why?
|
| Encephalitis | 2 | 2004 | 131 | 0.020 |
Why?
|
| Pain, Postoperative | 1 | 1988 | 247 | 0.020 |
Why?
|
| Psychomotor Disorders | 1 | 2005 | 17 | 0.020 |
Why?
|
| Perceptual Disorders | 1 | 2005 | 22 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2010 | 542 | 0.020 |
Why?
|
| Mandible | 1 | 1985 | 61 | 0.020 |
Why?
|
| Echinocandins | 1 | 2005 | 7 | 0.020 |
Why?
|
| Lipopeptides | 1 | 2005 | 13 | 0.020 |
Why?
|
| Torque | 1 | 2005 | 83 | 0.010 |
Why?
|
| DNA Mutational Analysis | 2 | 2001 | 379 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor Proteins | 1 | 2005 | 7 | 0.010 |
Why?
|
| Thiazolidines | 1 | 2005 | 9 | 0.010 |
Why?
|
| Dental Cementum | 1 | 1985 | 5 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2010 | 735 | 0.010 |
Why?
|
| Hypnotics and Sedatives | 1 | 1986 | 178 | 0.010 |
Why?
|
| CDC28 Protein Kinase, S cerevisiae | 1 | 2004 | 7 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1985 | 176 | 0.010 |
Why?
|
| Chemoprevention | 1 | 2005 | 91 | 0.010 |
Why?
|
| Administration, Oral | 2 | 1997 | 787 | 0.010 |
Why?
|
| 1-Butanol | 1 | 2004 | 2 | 0.010 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 156 | 0.010 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2005 | 113 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2004 | 47 | 0.010 |
Why?
|
| Dual Specificity Phosphatase 1 | 1 | 2004 | 26 | 0.010 |
Why?
|
| Pheromones | 1 | 2004 | 29 | 0.010 |
Why?
|
| Thiazoles | 1 | 2005 | 118 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2005 | 306 | 0.010 |
Why?
|
| Protein Phosphatase 1 | 1 | 2004 | 33 | 0.010 |
Why?
|
| GTP-Binding Proteins | 1 | 2005 | 158 | 0.010 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2004 | 53 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2004 | 73 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2005 | 269 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 1987 | 717 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 5468 | 0.010 |
Why?
|
| Factor Analysis, Statistical | 1 | 2004 | 284 | 0.010 |
Why?
|
| Electrochemistry | 1 | 2003 | 79 | 0.010 |
Why?
|
| Alcoholism | 1 | 2010 | 766 | 0.010 |
Why?
|
| Inositol | 1 | 2003 | 26 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 3 | 1990 | 1033 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2009 | 902 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 399 | 0.010 |
Why?
|
| Canada | 1 | 2004 | 353 | 0.010 |
Why?
|
| Hydrogen | 1 | 2003 | 65 | 0.010 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2005 | 217 | 0.010 |
Why?
|
| Dental Scaling | 1 | 1982 | 4 | 0.010 |
Why?
|
| Periodontal Pocket | 1 | 1982 | 8 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2004 | 402 | 0.010 |
Why?
|
| Tooth Root | 1 | 1982 | 13 | 0.010 |
Why?
|
| Consumer Product Safety | 1 | 2002 | 32 | 0.010 |
Why?
|
| Oral Health | 2 | 1975 | 123 | 0.010 |
Why?
|
| Fetus | 1 | 2007 | 782 | 0.010 |
Why?
|
| Nerve Regeneration | 1 | 1983 | 62 | 0.010 |
Why?
|
| Gels | 1 | 2002 | 83 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 1985 | 672 | 0.010 |
Why?
|
| Antigens, CD20 | 1 | 2002 | 27 | 0.010 |
Why?
|
| Epidermal Growth Factor | 1 | 1983 | 170 | 0.010 |
Why?
|
| Neuroglia | 1 | 2003 | 167 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2005 | 592 | 0.010 |
Why?
|
| Temperature | 1 | 2005 | 635 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2005 | 590 | 0.010 |
Why?
|
| Critical Care | 1 | 1986 | 552 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2004 | 457 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2004 | 650 | 0.010 |
Why?
|
| Affect | 1 | 2004 | 289 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2005 | 404 | 0.010 |
Why?
|
| Aid to Families with Dependent Children | 1 | 2001 | 4 | 0.010 |
Why?
|
| National Health Programs | 1 | 2001 | 17 | 0.010 |
Why?
|
| Leukocyte-Adhesion Deficiency Syndrome | 1 | 2001 | 2 | 0.010 |
Why?
|
| Microscopy | 1 | 1982 | 140 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2002 | 213 | 0.010 |
Why?
|
| Spinal Cord | 2 | 1999 | 355 | 0.010 |
Why?
|
| Dosage Compensation, Genetic | 1 | 2000 | 9 | 0.010 |
Why?
|
| Prolactinoma | 1 | 2000 | 12 | 0.010 |
Why?
|
| Mannose | 1 | 1980 | 25 | 0.010 |
Why?
|
| Tandem Repeat Sequences | 1 | 2000 | 18 | 0.010 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2000 | 42 | 0.010 |
Why?
|
| X Chromosome | 1 | 2000 | 50 | 0.010 |
Why?
|
| Cricetulus | 1 | 1980 | 107 | 0.010 |
Why?
|
| Cricetinae | 1 | 1980 | 280 | 0.010 |
Why?
|
| Dermatologic Agents | 1 | 2001 | 65 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2004 | 739 | 0.010 |
Why?
|
| Glutathione | 1 | 2002 | 349 | 0.010 |
Why?
|
| Th1 Cells | 1 | 2001 | 137 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2004 | 1716 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 2000 | 163 | 0.010 |
Why?
|
| Tidal Volume | 1 | 2000 | 85 | 0.010 |
Why?
|
| Species Specificity | 1 | 2001 | 568 | 0.010 |
Why?
|
| Th2 Cells | 1 | 2001 | 171 | 0.010 |
Why?
|
| Australia | 1 | 1980 | 243 | 0.010 |
Why?
|
| Cyclosporine | 1 | 2001 | 263 | 0.010 |
Why?
|
| Stomatitis, Aphthous | 1 | 1999 | 10 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 1999 | 41 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 2002 | 308 | 0.010 |
Why?
|
| Gingival Crevicular Fluid | 2 | 1982 | 2 | 0.010 |
Why?
|
| Medical Laboratory Personnel | 1 | 1999 | 7 | 0.010 |
Why?
|
| History, 20th Century | 1 | 1980 | 295 | 0.010 |
Why?
|
| Philippines | 1 | 1999 | 49 | 0.010 |
Why?
|
| Problem-Based Learning | 1 | 2000 | 82 | 0.010 |
Why?
|
| Ovary | 1 | 1980 | 209 | 0.010 |
Why?
|
| Phenotype | 1 | 2007 | 3062 | 0.010 |
Why?
|
| Quarantine | 1 | 1999 | 28 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 1999 | 161 | 0.010 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 1999 | 35 | 0.010 |
Why?
|
| Fetal Blood | 1 | 2001 | 318 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 1978 | 80 | 0.010 |
Why?
|
| Intracellular Membranes | 1 | 1978 | 83 | 0.010 |
Why?
|
| Tropomodulin | 1 | 1998 | 2 | 0.010 |
Why?
|
| Eosinophils | 1 | 2001 | 324 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 1999 | 179 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2006 | 1106 | 0.010 |
Why?
|
| Follicular Fluid | 1 | 1997 | 5 | 0.010 |
Why?
|
| DNA, Recombinant | 1 | 1998 | 46 | 0.010 |
Why?
|
| Ascitic Fluid | 1 | 1997 | 14 | 0.010 |
Why?
|
| Injections, Spinal | 1 | 1998 | 111 | 0.010 |
Why?
|
| Synovial Fluid | 1 | 1997 | 66 | 0.010 |
Why?
|
| Sarcomeres | 1 | 1998 | 93 | 0.010 |
Why?
|
| Rubella Vaccine | 1 | 1997 | 6 | 0.010 |
Why?
|
| Mumps Vaccine | 1 | 1997 | 13 | 0.010 |
Why?
|
| Measles Vaccine | 1 | 1997 | 19 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1997 | 117 | 0.010 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 1997 | 25 | 0.010 |
Why?
|
| Poverty | 1 | 2001 | 499 | 0.010 |
Why?
|
| Half-Life | 1 | 1997 | 162 | 0.010 |
Why?
|
| Vaccines, Combined | 1 | 1997 | 48 | 0.010 |
Why?
|
| Biological Availability | 1 | 1997 | 147 | 0.010 |
Why?
|
| Poliovirus Vaccine, Oral | 1 | 1997 | 25 | 0.010 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 1997 | 41 | 0.010 |
Why?
|
| Adenoviridae | 1 | 1998 | 193 | 0.010 |
Why?
|
| Bone Resorption | 2 | 1975 | 80 | 0.010 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 1 | 1996 | 1 | 0.010 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 6 | 1 | 1996 | 1 | 0.010 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 4 | 1 | 1996 | 4 | 0.010 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 1996 | 8 | 0.010 |
Why?
|
| Evolution, Molecular | 1 | 2000 | 462 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 1998 | 312 | 0.010 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 1996 | 38 | 0.010 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 1996 | 25 | 0.010 |
Why?
|
| Edrophonium | 1 | 1996 | 2 | 0.010 |
Why?
|
| Parasympathomimetics | 1 | 1996 | 3 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2001 | 858 | 0.010 |
Why?
|
| Immunization Schedule | 1 | 1997 | 197 | 0.010 |
Why?
|
| Visual Fields | 1 | 1996 | 87 | 0.010 |
Why?
|
| Mental Recall | 1 | 1997 | 191 | 0.010 |
Why?
|
| Transfection | 1 | 1998 | 918 | 0.010 |
Why?
|
| Insurance Coverage | 1 | 1997 | 220 | 0.010 |
Why?
|
| Tooth Diseases | 1 | 1975 | 13 | 0.010 |
Why?
|
| Complement C4 | 1 | 1995 | 25 | 0.010 |
Why?
|
| Receptors, Cholinergic | 1 | 1995 | 38 | 0.010 |
Why?
|
| Complement C5a | 1 | 1995 | 70 | 0.010 |
Why?
|
| Pan troglodytes | 1 | 1975 | 58 | 0.010 |
Why?
|
| Complement C3a | 1 | 1995 | 41 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 1999 | 602 | 0.010 |
Why?
|
| Educational Status | 1 | 1997 | 474 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1997 | 1311 | 0.010 |
Why?
|
| Serum Albumin | 1 | 1995 | 149 | 0.010 |
Why?
|
| Gingival Hyperplasia | 1 | 1973 | 3 | 0.010 |
Why?
|
| Exudates and Transudates | 1 | 1973 | 12 | 0.010 |
Why?
|
| Tissue Preservation | 1 | 1973 | 11 | 0.010 |
Why?
|
| Population Surveillance | 1 | 1997 | 439 | 0.010 |
Why?
|
| Complement C3 | 1 | 1995 | 208 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 1995 | 276 | 0.010 |
Why?
|
| Immunoglobulin A | 1 | 1995 | 201 | 0.010 |
Why?
|
| Vaccination | 1 | 2001 | 1348 | 0.010 |
Why?
|
| Cystic Fibrosis | 1 | 2001 | 1067 | 0.010 |
Why?
|
| Mutagenicity Tests | 1 | 1990 | 8 | 0.010 |
Why?
|
| Base Composition | 1 | 1990 | 76 | 0.010 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 1990 | 15 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1995 | 851 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 1990 | 103 | 0.010 |
Why?
|
| Karyotyping | 1 | 1990 | 99 | 0.010 |
Why?
|
| Introns | 1 | 1990 | 249 | 0.000 |
Why?
|
| Heterozygote | 1 | 1990 | 271 | 0.000 |
Why?
|
| Gene Frequency | 1 | 1990 | 500 | 0.000 |
Why?
|
| Infusions, Parenteral | 1 | 1988 | 38 | 0.000 |
Why?
|
| Lithium Chloride | 1 | 1987 | 12 | 0.000 |
Why?
|
| Abdomen | 1 | 1988 | 119 | 0.000 |
Why?
|
| Autoantibodies | 1 | 1995 | 1468 | 0.000 |
Why?
|
| Self Administration | 1 | 1987 | 122 | 0.000 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 1986 | 78 | 0.000 |
Why?
|
| Homosexuality | 1 | 1983 | 16 | 0.000 |
Why?
|
| Spinal Cord Neoplasms | 1 | 1983 | 37 | 0.000 |
Why?
|
| Toxoplasmosis | 1 | 1983 | 37 | 0.000 |
Why?
|
| Ganglia, Sympathetic | 1 | 1983 | 14 | 0.000 |
Why?
|
| Enzyme Induction | 1 | 1983 | 90 | 0.000 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 1983 | 71 | 0.000 |
Why?
|
| Periodontics | 1 | 1982 | 5 | 0.000 |
Why?
|
| Meningitis | 1 | 1983 | 79 | 0.000 |
Why?
|
| Pheochromocytoma | 1 | 1983 | 57 | 0.000 |
Why?
|
| Myelin Sheath | 1 | 1983 | 160 | 0.000 |
Why?
|
| Mitosis | 1 | 1983 | 180 | 0.000 |
Why?
|
| Astrocytes | 1 | 1983 | 197 | 0.000 |
Why?
|
| Oligodendroglia | 1 | 1983 | 167 | 0.000 |
Why?
|
| Nerve Tissue Proteins | 1 | 1983 | 569 | 0.000 |
Why?
|
| Tooth Erosion | 1 | 1975 | 3 | 0.000 |
Why?
|
| Dental Calculus | 1 | 1975 | 4 | 0.000 |
Why?
|
| Brain Neoplasms | 1 | 1983 | 1149 | 0.000 |
Why?
|
| Ribosomes | 1 | 1975 | 165 | 0.000 |
Why?
|
| Dental Caries | 1 | 1975 | 154 | 0.000 |
Why?
|
| Endoplasmic Reticulum | 1 | 1975 | 261 | 0.000 |
Why?
|